<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Obes Metab</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Obes Metab</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1463-1326</journal-id><journal-id journal-id-type="publisher-id">DOM</journal-id><journal-title-group><journal-title>Diabetes, Obesity &#x00026; Metabolism</journal-title></journal-title-group><issn pub-type="ppub">1462-8902</issn><issn pub-type="epub">1463-1326</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28345814</article-id><article-id pub-id-type="pmc">5575470</article-id><article-id pub-id-type="doi">10.1111/dom.12954</article-id><article-id pub-id-type="publisher-id">DOM12954</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: <styled-content style="fixed-case">S</styled-content>ustained reductions in body weight, glycaemia and blood pressure over 1&#x02009;year</article-title></title-group><contrib-group><contrib id="dom12954-cr-0001" contrib-type="author"><name><surname>Lundkvist</surname><given-names>Per</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12954-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12954-cr-0002" contrib-type="author"><name><surname>Pereira</surname><given-names>Maria J.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="dom12954-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12954-cr-0003" contrib-type="author"><name><surname>Katsogiannos</surname><given-names>Petros</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="dom12954-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="dom12954-cr-0004" contrib-type="author"><name><surname>Sj&#x000f6;str&#x000f6;m</surname><given-names>C. David</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="dom12954-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12954-cr-0005" contrib-type="author"><name><surname>Johnsson</surname><given-names>Eva</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="dom12954-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="dom12954-cr-0006" contrib-type="author" corresp="yes"><name><surname>Eriksson</surname><given-names>Jan W.</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2639-9481</contrib-id><address><email>jan.eriksson@medsci.uu.se</email></address><xref ref-type="aff" rid="dom12954-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="dom12954-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Medical Sciences</named-content>
<institution>Uppsala University</institution>
<named-content content-type="city">Uppsala</named-content>
<country country="SE">Sweden</country>
</aff><aff id="dom12954-aff-0002">
<label><sup>2</sup></label>
<institution>AstraZeneca</institution>
<named-content content-type="city">Gothenburg</named-content>
<country country="SE">Sweden</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold> Jan W. Eriksson MD, PhD, Department of Medical Sciences, Uppsala University, 75185 Uppsala, Sweden.Email: <email>jan.eriksson@medsci.uu.se</email></corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2017</year></pub-date><volume>19</volume><issue>9</issue><issue-id pub-id-type="doi">10.1111/dom.2017.19.issue-9</issue-id><fpage>1276</fpage><lpage>1288</lpage><history><date date-type="received"><day>18</day><month>1</month><year>2017</year></date><date date-type="rev-recd"><day>10</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>23</day><month>3</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 John Wiley & Sons Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>Diabetes, Obesity and Metabolism</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:DOM-19-1276.pdf"/><abstract id="dom12954-abs-0001"><sec id="dom12954-sec-0001"><title>Aims</title><p id="dom12954-para-0005">Dapagliflozin and exenatide reduce body weight by differing mechanisms. Dual therapy with these agents reduces body weight, adipose tissue volume, glycaemia and systolic blood pressure (<styled-content style="fixed-case">SBP</styled-content>) over 24&#x02009;weeks. Here, we examined these effects over 1&#x02009;year in obese adults without diabetes.</p></sec><sec id="dom12954-sec-0002"><title>Materials and methods</title><p id="dom12954-para-0006">Obese adults without diabetes (<styled-content style="fixed-case">N</styled-content>&#x02009;=&#x02009;50; aged 18&#x02010;70&#x02009;years; body mass index, 30&#x02010;45&#x02009;kg/m<sup>2</sup>) were initially randomized to double&#x02010;blind oral dapagliflozin 10&#x02009;mg once daily plus subcutaneous long&#x02010;acting exenatide 2&#x02009;mg once weekly or to placebo. They entered an open&#x02010;label extension from 24 to 52&#x02009;weeks during which all participants received active treatment.</p></sec><sec id="dom12954-sec-0003"><title>Results</title><p id="dom12954-para-0007">Of the original 25 dapagliflozin&#x02009;+&#x02009;exenatide&#x02010;treated and 25 placebo&#x02010;treated participants, respectively, 21 (84%) and 17 (68%) entered the open&#x02010;label period and 16 (64%) and 17 (68%) completed 52&#x02009;weeks of treatment. At baseline, mean body weight was 104.6&#x02009;kg, and 73.5% of participants had prediabetes (impaired fasting glucose or impaired glucose tolerance). Reductions with dapagliflozin&#x02009;+&#x02009;exenatide at 24&#x02009;weeks were sustained at 52&#x02009;weeks, respectively, for body weight (&#x02212;4.5 and &#x02212;5.7&#x02009;kg), total adipose tissue volume (&#x02212;3.8 and &#x02212;5.3&#x02009;L), proportion with prediabetes (34.8% and 35.3%), and <styled-content style="fixed-case">SBP</styled-content> (&#x02212;9.8 and &#x02212;12.0&#x02009;<styled-content style="fixed-case">mm Hg</styled-content>). Effects on body weight, <styled-content style="fixed-case">SBP</styled-content> and glycaemia at 52&#x02009;weeks with placebo&#x02009;&#x02192;&#x02009;dapagliflozin&#x02009;+&#x02009;exenatide were similar to those observed with continuation of dapagliflozin&#x02009;+&#x02009;exenatide. Nausea and injection&#x02010;site reactions were more frequent with dapagliflozin&#x02009;+&#x02009;exenatide than with placebo and diminished over time. Safety and tolerability were similar to that in previous diabetes trials with these agents. No clear difference in adverse event&#x02010;related withdrawals between placebo and active treatment periods was observed.</p></sec><sec id="dom12954-sec-0004"><title>Conclusions</title><p id="dom12954-para-0008">Dapagliflozin&#x02009;+&#x02009;exenatide dual therapy produced sustained reductions in body weight, prediabetes and <styled-content style="fixed-case">SBP</styled-content> over 52&#x02009;weeks and was well tolerated in obese adults without diabetes.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="dom12954-kwd-0001">dapagliflozin</kwd><kwd id="dom12954-kwd-0002">exenatide</kwd><kwd id="dom12954-kwd-0003">obesity</kwd><kwd id="dom12954-kwd-0004">prediabetes</kwd></kwd-group><funding-group><award-group><funding-source>AstraZeneca</funding-source></award-group><award-group><funding-source>Sanofi</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="13"/><word-count count="9012"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>dom12954</meta-value></custom-meta><custom-meta><meta-name>header-id</meta-name><meta-value>dom12954-hdr-0001</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.8 mode:remove_FC converted:30.08.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="dom12954-cit-1001">
<string-name>
<surname>Lundkvist</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pereira</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Katsogiannos</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sj&#x000f6;str&#x000f6;m</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Johnsson</surname>
<given-names>E</given-names>
</string-name> and <string-name>
<surname>Eriksson</surname>
<given-names>JW</given-names>
</string-name>. <article-title>Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1&#x02009;year</article-title>. <source>Diabetes Obes Metab</source>. <year>2017</year>;19:1276&#x02013;1288. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/dom.12954">https://doi.org/10.1111/dom.12954</ext-link>
</mixed-citation>
</p></notes><notes><fn-group id="dom12954-ntgp-0001"><fn id="dom12954-note-0001"><p>
<bold>Funding Information</bold> This study was supported by AstraZeneca.</p></fn></fn-group></notes></front><body><sec id="dom12954-sec-0005"><label>1</label><title>INTRODUCTION</title><p id="dom12954-para-0009">Overweight and obesity are highly prevalent worldwide, affecting 39% and 13% of adults, respectively,<xref rid="dom12954-bib-0001" ref-type="ref">1</xref> and are associated with serious health consequences, including type 2 diabetes (T2D), cardiovascular disease, non&#x02010;alcoholic fatty liver disease, musculoskeletal disorders and certain cancers.<xref rid="dom12954-bib-0001" ref-type="ref">1</xref>, <xref rid="dom12954-bib-0002" ref-type="ref">2</xref> Conversely, body weight loss of &#x02265;5% can mitigate cardiometabolic risk associated with overweight and obesity.<xref rid="dom12954-bib-0003" ref-type="ref">3</xref> Although intensive lifestyle interventions can achieve substantial reductions in body weight in the context of randomized controlled trials,<xref rid="dom12954-bib-0004" ref-type="ref">4</xref> results from real&#x02010;life primary care settings have been disappointing.<xref rid="dom12954-bib-0005" ref-type="ref">5</xref> Moreover, in response to body weight loss, physiological counter&#x02010;regulatory mechanisms, such as compensatory changes in energy intake and expenditure, undermine the long&#x02010;term maintenance of body weight loss.<xref rid="dom12954-bib-0006" ref-type="ref">6</xref> While pharmacological treatments may augment initial body weight loss and/or maintenance of body weight loss alongside behavioural interventions, there are concerns as to their longer&#x02010;term effectiveness and safety.<xref rid="dom12954-bib-0007" ref-type="ref">7</xref> Consequently, an unmet need exists for novel body weight loss interventions, including pharmacotherapies, used singly or in combination, that provide durable efficacy and are safe and well tolerated.<xref rid="dom12954-bib-0008" ref-type="ref">8</xref>
</p><p id="dom12954-para-0010">Some glucose&#x02010;lowering therapies induce body weight loss, prompting exploration of their use in obese individuals at risk of developing diabetes. Of particular interest are selective sodium&#x02010;glucose cotransporter 2 (SGLT2) inhibitors and glucagon&#x02010;like peptide&#x02010;1 receptor agonists (GLP&#x02010;1RAs),<xref rid="dom12954-bib-0009" ref-type="ref">9</xref>, <xref rid="dom12954-bib-0010" ref-type="ref">10</xref> which cause body weight loss via different mechanisms. SGLT2 inhibitors increase urinary glucose excretion, resulting in urinary caloric loss and minor fluid loss resulting from mild diuresis, but with a compensatory appetite increase,<xref rid="dom12954-bib-0011" ref-type="ref">11</xref>, <xref rid="dom12954-bib-0012" ref-type="ref">12</xref> whereas GLP&#x02010;1RAs reduce appetite and delay gastric emptying.<xref rid="dom12954-bib-0013" ref-type="ref">13</xref> The SGLT2 inhibitor dapagliflozin and the GLP&#x02010;1RA exenatide consistently reduce body weight in patients with T2D, which is maintained for up to 2<xref rid="dom12954-bib-0014" ref-type="ref">14</xref>, <xref rid="dom12954-bib-0015" ref-type="ref">15</xref>, <xref rid="dom12954-bib-0016" ref-type="ref">16</xref> and 6&#x02009;years,<xref rid="dom12954-bib-0017" ref-type="ref">17</xref>, <xref rid="dom12954-bib-0018" ref-type="ref">18</xref>, <xref rid="dom12954-bib-0019" ref-type="ref">19</xref> respectively.</p><p id="dom12954-para-0011">The differing and possibly complementary mechanisms of action of dapagliflozin and exenatide may be particularly effective when these agents are used in combination to achieve sustained body weight loss and prediabetes reduction.</p><p id="dom12954-para-0012">We previously reported the 24&#x02010;week results of a phase 2 randomized placebo&#x02010;controlled study comparing dual therapy with oral dapagliflozin 10&#x02009;mg once daily (DAPA) and subcutaneous exenatide 2&#x02009;mg once weekly (ExQW) vs placebo (PBO) in obese adults without diabetes (N&#x02009;=&#x02009;50).<xref rid="dom12954-bib-0020" ref-type="ref">20</xref> Those receiving DAPA&#x02009;+&#x02009;ExQW lost weight (&#x02212;4.5&#x02009;kg), whereas those receiving PBO did not (&#x02212;0.4&#x02009;kg), and 36% vs 0% of participants, respectively, achieved &#x02265;5% body weight loss. Body weight loss with DAPA&#x02009;+&#x02009;ExQW was largely accounted for by reduction in adipose tissue volume as assessed with magnetic resonance imaging (MRI). Improved glycaemic control and reduced blood pressure were also observed with DAPA&#x02009;+&#x02009;ExQW. No unexpected tolerability issues were found with the combination in this small proof&#x02010;of&#x02010;concept study.<xref rid="dom12954-bib-0020" ref-type="ref">20</xref>
</p><p id="dom12954-para-0013">Participants completing the 24&#x02010;week study who had adhered to the protocol were offered a further 28&#x02009;weeks of treatment with DAPA&#x02009;+&#x02009;ExQW in an open&#x02010;label extension of this study. Outcomes evaluated included change in body weight, body composition by MRI, measures of glycaemic control and cardiovascular risk, and safety and tolerability.</p></sec><sec id="dom12954-sec-0006"><label>2</label><title>METHODS</title><sec id="dom12954-sec-0007"><label>2.1</label><title>Study design and participants</title><p id="dom12954-para-0014">The design of this phase 2a study evaluating the efficacy and safety of dual therapy with DAPA&#x02009;+&#x02009;ExQW in obese participants without diabetes (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> identifier: NCT02313220) has been published previously.<xref rid="dom12954-bib-0020" ref-type="ref">20</xref> Briefly, this was an investigator&#x02010;initiated 24&#x02010;week, randomized, parallel&#x02010;group, double&#x02010;blind, placebo&#x02010;controlled trial followed by an optional 28&#x02010;week open&#x02010;label phase during which all participants received active treatment and had study visits at week 38 and 52 (Figure <xref rid="dom12954-fig-0001" ref-type="fig">1</xref>A). It was conducted at a single centre in Sweden from December 2014 to March 2016. Participants were obese (body mass index [BMI], 30&#x02010;45&#x02009;kg/m<sup>2</sup>), were aged 18 to 70&#x02009;years and did not have diabetes.</p><fig fig-type="Figure" xml:lang="en" id="dom12954-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>
<styled-content style="fixed-case">A</styled-content>, <styled-content style="fixed-case">S</styled-content>tudy design and <styled-content style="fixed-case">B</styled-content>, <styled-content style="fixed-case">CONSORT</styled-content> flow diagram. <styled-content style="fixed-case">DAPA</styled-content>&#x02009;+&#x02009;<styled-content style="fixed-case">ExQW</styled-content>, dapagliflozin 10&#x02009;mg once daily plus exenatide 2&#x02009;mg once weekly; <styled-content style="fixed-case">ITT</styled-content>, intention to treat; <styled-content style="fixed-case">PBO</styled-content>, placebo; <styled-content style="fixed-case">QD</styled-content>, once daily; <styled-content style="fixed-case">QW</styled-content>, once weekly. *A profound lifestyle change, including a strict low&#x02010;carbohydrate/high&#x02010;fat diet that elevated blood ketones. This resulted in withdrawal of this patient during blinded study phase and exclusion of this patient from the full analysis set</p></caption><graphic id="nlm-graphic-1" xlink:href="DOM-19-1276-g001"/></fig></sec><sec id="dom12954-sec-0008"><label>2.2</label><title>Treatments</title><p id="dom12954-para-0015">Following the 24&#x02010;week double&#x02010;blind phase, all eligible participants receiving PBO and DAPA&#x02009;+&#x02009;ExQW were offered 28&#x02009;weeks of open&#x02010;label DAPA&#x02009;+&#x02009;ExQW treatment (hereafter referred to as PBO&#x02009;&#x02192;&#x02009;DAPA&#x02009;+&#x02009;ExQW and continued DAPA&#x02009;+&#x02009;ExQW groups, respectively). Details on randomization procedure, blinding, ethics and informed consent, and guidelines for comedication usage have been published previously.<xref rid="dom12954-bib-0020" ref-type="ref">20</xref> Patients received oral and written instructions to follow national guidelines on a balanced normo&#x02010;caloric diet, and moderate exercise (eg, walking 30&#x02009;minutes most days) was recommended. Because the primary purpose of this proof&#x02010;of&#x02010;concept study was to evaluate pharmacological effects, diet and exercise modification was not strictly reinforced or monitored.</p></sec><sec id="dom12954-sec-0009"><label>2.3</label><title>Outcomes</title><p id="dom12954-para-0016">Details of outcome measures have been published previously<xref rid="dom12954-bib-0020" ref-type="ref">20</xref>; however, a brief description is provided below.</p><sec id="dom12954-sec-0010"><label>2.3.1</label><title>Efficacy</title><p id="dom12954-para-0017">Primary and secondary endpoints were change and percent change in body weight (kg) from baseline to 52&#x02009;weeks and from 24 to 52&#x02009;weeks. Exploratory efficacy endpoints included proportions of participants achieving &#x02265;5% and &#x02265;10% body weight loss; changes in waist circumference and waist&#x02010;to&#x02010;hip ratio; MRI&#x02010;assessed changes (continued DAPA&#x02009;+&#x02009;ExQW group only) in total adipose and lean tissue volumes, abdominal visceral and subcutaneous adipose tissue volumes, and liver fat percent (defined as liver fat&#x02009;&#x000d7;&#x02009;100&#x02009;&#x000f7;&#x02009;[liver fat&#x02009;+&#x02009;liver water]); changes in glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG); changes in oral glucose tolerance test (OGTT)&#x02010;derived measures (continued DAPA&#x02009;+&#x02009;ExQW group only), including 2&#x02010;hour plasma glucose (2&#x02010;hour PG), proportions with impaired fasting glucose (IFG; defined as FPG&#x02009;&#x02265;&#x02009;5.6&#x02009;mmol/L measured just before the OGTT), or impaired glucose tolerance (IGT; defined as a PG value&#x02009;&#x02265;&#x02009;7.8&#x02009;mmol/L measured 120&#x02009;minutes after initiation of OGTT) or any IFG/IGT (prediabetes); changes in seated systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate; and changes in fasting serum lipids.</p></sec><sec id="dom12954-sec-0011"><label>2.3.2</label><title>Safety</title><p id="dom12954-para-0018">Reports of adverse events (AEs) were collected and coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 18.0E. Furthermore, AEs of special interest for dapagliflozin and exenatide treatment (urinary tract infections [UTIs], genital infections, events related to volume reduction, changes in renal function and gastrointestinal symptomatology) were captured using prespecified lists of relevant MedDRA&#x02010;preferred terms. Changes in laboratory parameters of interest were also measured.</p></sec></sec><sec id="dom12954-sec-0012"><label>2.4</label><title>Statistical methods</title><p id="dom12954-para-0019">Primary, secondary and exploratory efficacy endpoints were analysed with an intention&#x02010;to&#x02010;treat (ITT) approach, using all available data comprising the full analysis set. Analyses of safety employed the safety analysis set. For definitions of analysis sets, see File S1 (Supplementary Statistical Methods). For efficacy endpoints, adjusted mean changes from 0 to 24&#x02009;weeks, 24 to 52&#x02009;weeks and 0 to 52&#x02009;weeks, and associated 95% confidence intervals (CIs) and <italic>P</italic> values for comparison between time points, were derived from a mixed model for repeated measures (MMRM) with treatment, week, treatment&#x02010;by&#x02010;week interaction and sex as categorical fixed covariates and baseline value as a continuous fixed covariate. The same approach was used for analysis of changes in HbA1c, FPG, blood pressure, heart rate and fasting serum lipids. For the open&#x02010;label extension phase, no between&#x02010;group comparisons were made. During the extension period, MRI and OGTT&#x02010;derived measurements were available only for the continuing DAPA&#x02009;+&#x02009;ExQW group; therefore, MMRM did not contain treatment terms.</p><p id="dom12954-para-0020">Paired McNemar tests were used to evaluate proportions of participants with IFG and IGT (continuing DAPA&#x02009;+&#x02009;ExQW group only) after 24 and 52&#x02009;weeks.</p><p id="dom12954-para-0021">To assess potential bias from differential dropout rates in this delayed&#x02010;start study,<xref rid="dom12954-bib-0021" ref-type="ref">21</xref> sensitivity analyses were conducted for the primary endpoint. For further details, see File S1 (Sensitivity Analysis Methods; Sensitivity Analysis Results).</p><p id="dom12954-para-0022">All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, North Carolina). CIs and <italic>P</italic> values were unadjusted for multiple comparisons.</p></sec></sec><sec id="dom12954-sec-0013"><label>3</label><title>RESULTS</title><sec id="dom12954-sec-0014"><label>3.1</label><title>Participants</title><p id="dom12954-para-0023">Of the 50 participants randomized, 23 (92%) and 20 (80%) completed 24&#x02009;weeks of double&#x02010;blind treatment with DAPA&#x02009;+&#x02009;ExQW or PBO, respectively. Of these, 21 participants (84%) continued DAPA&#x02009;+&#x02009;ExQW (2 no longer met study criteria) and 17 (68%) switched from PBO to active treatment (PBO&#x02009;&#x02192;&#x02009;DAPA&#x02009;+&#x02009;ExQW) (1 had developed diabetes, 1 had skin rash and 1 declined to participate) during the open&#x02010;label extension period (Figure <xref rid="dom12954-fig-0001" ref-type="fig">1</xref>B). At the end of 52&#x02009;weeks, 16 participants (64%) in the original DAPA&#x02009;+&#x02009;ExQW group (5 discontinued prematurely, 4 because of AEs and 1 because of participant&#x02010;perceived lack of efficacy) and 17 participants (68%) in the original PBO&#x02009;group completed DAPA&#x02009;+&#x02009;ExQW treatment.</p><p id="dom12954-para-0024">Baseline demographic, anthropomorphic, body composition and glycaemic characteristics of the study participants have been published previously<xref rid="dom12954-bib-0020" ref-type="ref">20</xref>; the mean age of participants was 51.4&#x02009;years, mean BMI was 35.4&#x02009;kg/m<sup>2</sup> and 60% were female. At baseline, glycaemic variables, vital signs and renal function were balanced across treatment groups; however, participants in the DAPA&#x02009;+&#x02009;ExQW group were older and had greater body weight, body fat measures and duration of obesity (Table <xref rid="dom12954-supitem-0001" ref-type="supplementary-material">S1</xref> in File S1). One participant in each treatment arm, neither of whom entered the study extension, were using concomitant lipid&#x02010;lowering agents on entering the 0&#x02010; to 24&#x02010;week study. Two participants, both in the PBO&#x02009;&#x02192;&#x02009;DAPA&#x02009;+&#x02009;ExQW group, received atorvastatin at week 13 and at initiation of the extension, respectively. In the PBO&#x02009;&#x02192;&#x02009;DAPA&#x02009;+&#x02009;ExQW group, antihypertensives were newly prescribed or increased in 4 and 2 participants during the 0&#x02010; to 24&#x02010; and 24&#x02010; to 52&#x02010;week periods, respectively. In the continued DAPA&#x02009;+&#x02009;ExQW group, 3 participants altered use of antihypertensives during the 0&#x02010; to 24&#x02010;week period (1 discontinued, 1 discontinued and then restarted, and 1 received a new prescription) and none altered use of antihypertensives thereafter.</p></sec><sec id="dom12954-sec-0015"><label>3.2</label><title>Efficacy</title><sec id="dom12954-sec-0016"><label>3.2.1</label><title>Body weight</title><p id="dom12954-para-0025">Among participants continuing on DAPA&#x02009;+&#x02009;ExQW, body weight loss achieved at 24&#x02009;weeks (&#x02212;4.5&#x02009;kg) was sustained at 52&#x02009;weeks (&#x02212;5.7&#x02009;kg), with some additional body weight loss from 24 to 52&#x02009;weeks (&#x02212;1.2&#x02009;kg) that did not reach statistical significance (Table <xref rid="dom12954-tbl-0001" ref-type="table-wrap">1</xref>, Figure <xref rid="dom12954-fig-0002" ref-type="fig">2</xref>A). Participants who switched from placebo to active treatment (PBO&#x02009;&#x02192;&#x02009;DAPA&#x02009;+&#x02009;ExQW) at 24&#x02009;weeks achieved body weight loss at 52&#x02009;weeks (&#x02212;4.2&#x02009;kg) comparable to that with DAPA&#x02009;+&#x02009;ExQW during the first 24&#x02009;weeks of therapy (&#x02212;4.5&#x02009;kg). Similar results were obtained for body weight percentage changes (Figure <xref rid="dom12954-fig-0002" ref-type="fig">2</xref>B). When examining individual trajectories of body weight change over time, 76.5% of participants (complete case analysis; 52.0%, ITT analysis) continuing on DAPA&#x02009;+&#x02009;ExQW showed sustained weight loss of any magnitude over 52&#x02009;weeks, with 3 of these participants achieving a loss of &#x02265;15% of initial body weight (Figure <xref rid="dom12954-fig-0002" ref-type="fig">2</xref>C,D). Results of sensitivity analyses are shown in Figure <xref rid="dom12954-supitem-0001" ref-type="supplementary-material">S1</xref> of File <xref rid="dom12954-supitem-0001" ref-type="supplementary-material">S1</xref>.</p><table-wrap id="dom12954-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Findings for efficacy endpoints after 24 and 52&#x02009;weeks (full analysis set)</p></caption><table frame="hsides" rules="groups"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th style="border-bottom:solid 1px #000000" align="left" id="dom12954-ent-0001" valign="bottom" rowspan="1" colspan="1"/><th colspan="3" align="left" id="dom12954-ent-0002" valign="bottom" rowspan="1">Dapagliflozin 10&#x02009;mg QD&#x02009;+&#x02009;exenatide 2&#x02009;mg QW (n&#x02009;=&#x02009;25)</th><th colspan="3" align="left" id="dom12954-ent-0003" valign="bottom" rowspan="1">Placebo/dapagliflozin 10&#x02009;mg QD&#x02009;+&#x02009;exenatide 2&#x02009;mg QW (n&#x02009;=&#x02009;24)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" id="dom12954-ent-0004" valign="bottom" rowspan="1" colspan="1"/><th align="left" id="dom12954-ent-0005" valign="bottom" rowspan="1" colspan="1">Weeks 0 to 24</th><th align="left" id="dom12954-ent-0006" valign="bottom" rowspan="1" colspan="1">Weeks 24 to 52</th><th align="left" id="dom12954-ent-0007" valign="bottom" rowspan="1" colspan="1">Weeks 0 to 52</th><th align="left" id="dom12954-ent-0008" valign="bottom" rowspan="1" colspan="1">Weeks 0 to 24</th><th align="left" id="dom12954-ent-0009" valign="bottom" rowspan="1" colspan="1">Weeks 24 to 52</th><th align="left" id="dom12954-ent-0010" valign="bottom" rowspan="1" colspan="1">Weeks 0 to 52</th></tr></thead><tbody valign="top"><tr><td colspan="7" align="left" id="dom12954-ent-0011" valign="top" rowspan="1">
<bold>Primary endpoint</bold>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0012" valign="top" rowspan="1" colspan="1">Body weight, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0004">a</xref> kg</td><td align="left" id="dom12954-ent-0013" valign="top" rowspan="1" colspan="1">&#x02212;4.48 (&#x02212;6.09, &#x02212;2.88)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0014" valign="top" rowspan="1" colspan="1">&#x02212;1.21 (&#x02212;3.19, 0.78)</td><td align="left" id="dom12954-ent-0015" valign="top" rowspan="1" colspan="1">&#x02212;5.69 (&#x02212;8.63, &#x02212;2.75)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0016" valign="top" rowspan="1" colspan="1">&#x02212;0.34 (&#x02212;2.02, 1.33)</td><td align="left" id="dom12954-ent-0017" valign="top" rowspan="1" colspan="1">&#x02212;3.80 (&#x02212;5.85, &#x02212;1.75)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0018" valign="top" rowspan="1" colspan="1">&#x02212;4.15 (&#x02212;7.19, &#x02212;1.10)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td></tr><tr><td colspan="7" align="left" id="dom12954-ent-0019" valign="top" rowspan="1">
<bold>Secondary endpoint</bold>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0020" valign="top" rowspan="1" colspan="1">Body weight, adjusted mean percent change (95% CI),<xref ref-type="fn" rid="dom12954-note-0004">a</xref> %</td><td align="left" id="dom12954-ent-0021" valign="top" rowspan="1" colspan="1">&#x02212;4.47 (&#x02212;6.05, &#x02212;2.90)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0022" valign="top" rowspan="1" colspan="1">&#x02212;1.19 (&#x02212;3.00, 0.63)</td><td align="left" id="dom12954-ent-0023" valign="top" rowspan="1" colspan="1">&#x02212;5.66 (&#x02212;8.43, &#x02212;2.89)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0024" valign="top" rowspan="1" colspan="1">&#x02212;0.27 (&#x02212;1.91, 1.37)</td><td align="left" id="dom12954-ent-0025" valign="top" rowspan="1" colspan="1">&#x02212;3.80 (&#x02212;5.68, &#x02212;1.92)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0026" valign="top" rowspan="1" colspan="1">&#x02212;4.07 (&#x02212;6.94, &#x02212;1.21)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td></tr><tr><td colspan="7" align="left" id="dom12954-ent-0027" valign="top" rowspan="1">
<bold>Exploratory endpoints</bold>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0028" valign="top" rowspan="1" colspan="1">Body weight, proportion with &#x02265;5% reduction, n (%)</td><td align="left" id="dom12954-ent-0029" valign="top" rowspan="1" colspan="1">9/23 (39.1)</td><td align="left" id="dom12954-ent-0030" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0031" valign="top" rowspan="1" colspan="1">10/17 (58.8)</td><td align="left" id="dom12954-ent-0032" valign="top" rowspan="1" colspan="1">0/20 (0)</td><td align="left" id="dom12954-ent-0033" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0034" valign="top" rowspan="1" colspan="1">7/17 (41.2)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0035" valign="top" rowspan="1" colspan="1">Missing, n</td><td align="left" id="dom12954-ent-0036" valign="top" rowspan="1" colspan="1">2</td><td align="left" id="dom12954-ent-0037" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12954-ent-0038" valign="top" rowspan="1" colspan="1">8</td><td align="left" id="dom12954-ent-0039" valign="top" rowspan="1" colspan="1">4</td><td align="left" id="dom12954-ent-0040" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12954-ent-0041" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0042" valign="top" rowspan="1" colspan="1">Body weight, proportion with &#x02265;10% reduction, n (%)</td><td align="left" id="dom12954-ent-0043" valign="top" rowspan="1" colspan="1">3/23 (13.0)</td><td align="left" id="dom12954-ent-0044" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0045" valign="top" rowspan="1" colspan="1">3/17 (17.6)</td><td align="left" id="dom12954-ent-0046" valign="top" rowspan="1" colspan="1">0/20 (0)</td><td align="left" id="dom12954-ent-0047" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0048" valign="top" rowspan="1" colspan="1">4/17 (23.5)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0049" valign="top" rowspan="1" colspan="1">Missing, n</td><td align="left" id="dom12954-ent-0050" valign="top" rowspan="1" colspan="1">2</td><td align="left" id="dom12954-ent-0051" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12954-ent-0052" valign="top" rowspan="1" colspan="1">8</td><td align="left" id="dom12954-ent-0053" valign="top" rowspan="1" colspan="1">4</td><td align="left" id="dom12954-ent-0054" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12954-ent-0055" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0056" valign="top" rowspan="1" colspan="1">Waist circumference, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0004">a</xref> cm</td><td align="left" id="dom12954-ent-0057" valign="top" rowspan="1" colspan="1">&#x02212;5.3 (&#x02212;7.4, &#x02212;3.1)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0058" valign="top" rowspan="1" colspan="1">&#x02212;2.0 (&#x02212;4.7, 0.7)</td><td align="left" id="dom12954-ent-0059" valign="top" rowspan="1" colspan="1">&#x02212;7.3 (&#x02212;10.5, &#x02212;4.1)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0060" valign="top" rowspan="1" colspan="1">&#x02212;2.5 (&#x02212;4.8, &#x02212;0.2)<xref ref-type="fn" rid="dom12954-note-0003">*</xref>
</td><td align="left" id="dom12954-ent-0061" valign="top" rowspan="1" colspan="1">&#x02212;4.2 (&#x02212;7.0, &#x02212;1.4)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td><td align="left" id="dom12954-ent-0062" valign="top" rowspan="1" colspan="1">&#x02212;6.7 (&#x02212;10.0, &#x02212;3.3)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0063" valign="top" rowspan="1" colspan="1">Waist&#x02010;to&#x02010;hip ratio, adjusted mean change (95% CI)<xref ref-type="fn" rid="dom12954-note-0004">a</xref>
</td><td align="left" id="dom12954-ent-0064" valign="top" rowspan="1" colspan="1">&#x02212;0.02 (&#x02212;0.04, 0.001)</td><td align="left" id="dom12954-ent-0065" valign="top" rowspan="1" colspan="1">&#x02212;0.01 (&#x02212;0.03, 0.01)</td><td align="left" id="dom12954-ent-0066" valign="top" rowspan="1" colspan="1">&#x02212;0.03 (&#x02212;0.05, &#x02212;0.01)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td><td align="left" id="dom12954-ent-0067" valign="top" rowspan="1" colspan="1">&#x02212;0.01 (&#x02212;0.03, 0.01)</td><td align="left" id="dom12954-ent-0068" valign="top" rowspan="1" colspan="1">&#x02212;0.02 (&#x02212;0.04, 0.01)</td><td align="left" id="dom12954-ent-0069" valign="top" rowspan="1" colspan="1">&#x02212;0.03 (&#x02212;0.05, &#x02212;0.01)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td></tr><tr><td colspan="7" align="left" style="padding-left:10%" id="dom12954-ent-0070" valign="top" rowspan="1">
<italic><bold>MRI body composition</bold></italic>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0071" valign="top" rowspan="1" colspan="1">VAAT, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0005">b</xref> L</td><td align="left" id="dom12954-ent-0072" valign="top" rowspan="1" colspan="1">&#x02212;0.37 (&#x02212;0.64, &#x02212;0.09)<xref ref-type="fn" rid="dom12954-note-0003">*</xref>
</td><td align="left" id="dom12954-ent-0073" valign="top" rowspan="1" colspan="1">&#x02212;0.16 (&#x02212;0.45, 0.13)</td><td align="left" id="dom12954-ent-0074" valign="top" rowspan="1" colspan="1">&#x02212;0.53 (&#x02212;1.00, &#x02212;0.05)<xref ref-type="fn" rid="dom12954-note-0003">*</xref>
</td><td align="left" id="dom12954-ent-0075" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0076" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0077" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0078" valign="top" rowspan="1" colspan="1">SAAT,<xref ref-type="fn" rid="dom12954-note-0006">c</xref> adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0005">b</xref> L</td><td align="left" id="dom12954-ent-0079" valign="top" rowspan="1" colspan="1">&#x02212;1.24 (&#x02212;1.83, &#x02212;0.66)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0080" valign="top" rowspan="1" colspan="1">&#x02212;0.35 (&#x02212;0.82, 0.12)</td><td align="left" id="dom12954-ent-0081" valign="top" rowspan="1" colspan="1">&#x02212;1.59 (&#x02212;2.55, &#x02212;0.64)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td><td align="left" id="dom12954-ent-0082" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0083" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0084" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0085" valign="top" rowspan="1" colspan="1">Total adipose tissue, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0005">b</xref> L</td><td align="left" id="dom12954-ent-0086" valign="top" rowspan="1" colspan="1">&#x02212;3.80 (&#x02212;5.85, &#x02212;1.75)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td><td align="left" id="dom12954-ent-0087" valign="top" rowspan="1" colspan="1">&#x02212;1.51 (&#x02212;3.34, 0.32)</td><td align="left" id="dom12954-ent-0088" valign="top" rowspan="1" colspan="1">&#x02212;5.31 (&#x02212;8.90, &#x02212;1.72)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td><td align="left" id="dom12954-ent-0089" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0090" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0091" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0092" valign="top" rowspan="1" colspan="1">Total lean tissue, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0005">b</xref> L</td><td align="left" id="dom12954-ent-0093" valign="top" rowspan="1" colspan="1">&#x02212;1.04 (&#x02212;1.67, &#x02212;0.40)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td><td align="left" id="dom12954-ent-0094" valign="top" rowspan="1" colspan="1">&#x02212;0.32 (&#x02212;1.04, 0.40)</td><td align="left" id="dom12954-ent-0095" valign="top" rowspan="1" colspan="1">&#x02212;1.36 (&#x02212;2.19, &#x02212;0.52)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td><td align="left" id="dom12954-ent-0096" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0097" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0098" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0099" valign="top" rowspan="1" colspan="1">Liver fat, adjusted mean percent change (95% CI),<xref ref-type="fn" rid="dom12954-note-0005">b</xref> %</td><td align="left" id="dom12954-ent-0100" valign="top" rowspan="1" colspan="1">&#x02212;1.22 (&#x02212;2.70, 0.25)</td><td align="left" id="dom12954-ent-0101" valign="top" rowspan="1" colspan="1">&#x02212;0.31 (&#x02212;2.23, 1.60)</td><td align="left" id="dom12954-ent-0102" valign="top" rowspan="1" colspan="1">&#x02212;1.54 (&#x02212;3.24, 0.17)</td><td align="left" id="dom12954-ent-0103" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0104" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0105" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td colspan="7" align="left" style="padding-left:10%" id="dom12954-ent-0106" valign="top" rowspan="1">
<italic><bold>Glycaemic measures</bold></italic>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0107" valign="top" rowspan="1" colspan="1">HbA1c, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0004">a</xref> mmol/mol</td><td align="left" id="dom12954-ent-0108" valign="top" rowspan="1" colspan="1">&#x02212;3.9 (&#x02212;4.7, &#x02212;3.0)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0109" valign="top" rowspan="1" colspan="1">0.8 (&#x02212;0.1, 1.6)</td><td align="left" id="dom12954-ent-0110" valign="top" rowspan="1" colspan="1">&#x02212;3.1 (&#x02212;3.9, &#x02212;2.3)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0111" valign="top" rowspan="1" colspan="1">&#x02212;1.6 (&#x02212;2.4, &#x02212;0.7)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0112" valign="top" rowspan="1" colspan="1">&#x02212;1.6 (&#x02212;2.5, &#x02212;0.7)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0113" valign="top" rowspan="1" colspan="1">&#x02212;3.2 (&#x02212;4.1, &#x02212;2.3)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0114" valign="top" rowspan="1" colspan="1">HbA1c, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0004">a</xref> %</td><td align="left" id="dom12954-ent-0115" valign="top" rowspan="1" colspan="1">&#x02212;0.36 (&#x02212;0.43, &#x02212;0.27)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0116" valign="top" rowspan="1" colspan="1">0.07 (&#x02212;0.01, 0.15)</td><td align="left" id="dom12954-ent-0117" valign="top" rowspan="1" colspan="1">&#x02212;0.28 (&#x02212;0.36, &#x02212;0.21)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0118" valign="top" rowspan="1" colspan="1">&#x02212;0.15 (&#x02212;0.22, &#x02212;0.06)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0119" valign="top" rowspan="1" colspan="1">&#x02212;0.15 (&#x02212;0.23, &#x02212;0.06)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0120" valign="top" rowspan="1" colspan="1">&#x02212;0.29 (&#x02212;0.38, &#x02212;0.21)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0121" valign="top" rowspan="1" colspan="1">FPG, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0004">a</xref> mmol/L</td><td align="left" id="dom12954-ent-0122" valign="top" rowspan="1" colspan="1">&#x02212;0.41 (&#x02212;0.60, &#x02212;0.22)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0123" valign="top" rowspan="1" colspan="1">0.10 (&#x02212;0.10, 0.31)</td><td align="left" id="dom12954-ent-0124" valign="top" rowspan="1" colspan="1">&#x02212;0.31 (&#x02212;0.48, &#x02212;0.13)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td><td align="left" id="dom12954-ent-0125" valign="top" rowspan="1" colspan="1">0.25 (0.05, 0.45)<xref ref-type="fn" rid="dom12954-note-0003">*</xref>
</td><td align="left" id="dom12954-ent-0126" valign="top" rowspan="1" colspan="1">&#x02212;0.50 (&#x02212;0.71, &#x02212;0.29)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0127" valign="top" rowspan="1" colspan="1">&#x02212;0.25 (&#x02212;0.42, &#x02212;0.07)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0128" valign="top" rowspan="1" colspan="1">2&#x02010;h PG, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0005">b</xref> mmol/L</td><td align="left" id="dom12954-ent-0129" valign="top" rowspan="1" colspan="1">&#x02212;1.85 (&#x02212;2.62, &#x02212;1.08)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0130" valign="top" rowspan="1" colspan="1">&#x02212;0.37 (&#x02212;1.02, 0.29)</td><td align="left" id="dom12954-ent-0131" valign="top" rowspan="1" colspan="1">&#x02212;2.22 (&#x02212;2.98, &#x02212;1.45)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0132" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0133" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0134" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0135" valign="top" rowspan="1" colspan="1">Proportion with IFG, n/N (%)<xref ref-type="fn" rid="dom12954-note-0007">d</xref>
</td><td align="left" id="dom12954-ent-0136" valign="top" rowspan="1" colspan="1">8/23 (34.8)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td><td align="left" id="dom12954-ent-0137" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0138" valign="top" rowspan="1" colspan="1">6/17 (35.3)</td><td align="left" id="dom12954-ent-0139" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0140" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0141" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0142" valign="top" rowspan="1" colspan="1">Missing, n</td><td align="left" id="dom12954-ent-0143" valign="top" rowspan="1" colspan="1">2</td><td align="left" id="dom12954-ent-0144" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12954-ent-0145" valign="top" rowspan="1" colspan="1">8</td><td align="left" id="dom12954-ent-0146" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12954-ent-0147" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12954-ent-0148" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0149" valign="top" rowspan="1" colspan="1">Proportion with IGT, n/N (%)<xref ref-type="fn" rid="dom12954-note-0007">d</xref>
</td><td align="left" id="dom12954-ent-0150" valign="top" rowspan="1" colspan="1">4/23 (17.4)<xref ref-type="fn" rid="dom12954-note-0003">*</xref>
</td><td align="left" id="dom12954-ent-0151" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0152" valign="top" rowspan="1" colspan="1">2/15 (13.3)<xref ref-type="fn" rid="dom12954-note-0003">*</xref>
</td><td align="left" id="dom12954-ent-0153" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0154" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0155" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0156" valign="top" rowspan="1" colspan="1">Missing, n</td><td align="left" id="dom12954-ent-0157" valign="top" rowspan="1" colspan="1">2</td><td align="left" id="dom12954-ent-0158" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12954-ent-0159" valign="top" rowspan="1" colspan="1">10</td><td align="left" id="dom12954-ent-0160" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12954-ent-0161" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12954-ent-0162" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0163" valign="top" rowspan="1" colspan="1">Proportion with any IFG or IGT (prediabetes), n/N (%)</td><td align="left" id="dom12954-ent-0164" valign="top" rowspan="1" colspan="1">8/23 (34.8)</td><td align="left" id="dom12954-ent-0165" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0166" valign="top" rowspan="1" colspan="1">6/17 (35.3)<xref ref-type="fn" rid="dom12954-note-0003">*</xref>
</td><td align="left" id="dom12954-ent-0167" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0168" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0169" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0170" valign="top" rowspan="1" colspan="1">Missing, n</td><td align="left" id="dom12954-ent-0171" valign="top" rowspan="1" colspan="1">2</td><td align="left" id="dom12954-ent-0172" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12954-ent-0173" valign="top" rowspan="1" colspan="1">8</td><td align="left" id="dom12954-ent-0174" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12954-ent-0175" valign="top" rowspan="1" colspan="1"/><td align="left" id="dom12954-ent-0176" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0177" valign="top" rowspan="1" colspan="1">Urinary glucose excretion,<xref ref-type="fn" rid="dom12954-note-0008">e</xref> mean (SD), mmol/3&#x02009;h</td><td align="left" id="dom12954-ent-0178" valign="top" rowspan="1" colspan="1">50.5 (31.4)</td><td align="left" id="dom12954-ent-0179" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0180" valign="top" rowspan="1" colspan="1">45.7 (29.3)</td><td align="left" id="dom12954-ent-0181" valign="top" rowspan="1" colspan="1">0.3 (0.8)</td><td align="left" id="dom12954-ent-0182" valign="top" rowspan="1" colspan="1">NA</td><td align="left" id="dom12954-ent-0183" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td colspan="7" align="left" style="padding-left:10%" id="dom12954-ent-0184" valign="top" rowspan="1">
<italic><bold>Vital signs</bold></italic>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0185" valign="top" rowspan="1" colspan="1">Diastolic BP, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0004">a</xref> mm Hg</td><td align="left" id="dom12954-ent-0186" valign="top" rowspan="1" colspan="1">1.6 (&#x02212;2.8, 6.0)</td><td align="left" id="dom12954-ent-0187" valign="top" rowspan="1" colspan="1">&#x02212;0.2 (&#x02212;4.3, 3.9)</td><td align="left" id="dom12954-ent-0188" valign="top" rowspan="1" colspan="1">1.4 (&#x02212;2.5, 5.2)</td><td align="left" id="dom12954-ent-0189" valign="top" rowspan="1" colspan="1">2.4 (&#x02212;2.4, 7.1)</td><td align="left" id="dom12954-ent-0190" valign="top" rowspan="1" colspan="1">&#x02212;1.6 (&#x02212;5.9, 2.7)</td><td align="left" id="dom12954-ent-0191" valign="top" rowspan="1" colspan="1">0.8 (&#x02212;3.2, 4.7)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0192" valign="top" rowspan="1" colspan="1">Systolic BP, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0004">a</xref> mm Hg</td><td align="left" id="dom12954-ent-0193" valign="top" rowspan="1" colspan="1">&#x02212;9.8 (&#x02212;13.7, &#x02212;5.8)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0194" valign="top" rowspan="1" colspan="1">&#x02212;2.2 (&#x02212;7.9, 3.4)</td><td align="left" id="dom12954-ent-0195" valign="top" rowspan="1" colspan="1">&#x02212;12.0 (&#x02212;17.5, &#x02212;6.5)<xref ref-type="fn" rid="dom12954-note-0003b">***</xref>
</td><td align="left" id="dom12954-ent-0196" valign="top" rowspan="1" colspan="1">&#x02212;3.1 (&#x02212;7.2, 1.1)</td><td align="left" id="dom12954-ent-0197" valign="top" rowspan="1" colspan="1">&#x02212;4.1 (&#x02212;9.9, 1.7)</td><td align="left" id="dom12954-ent-0198" valign="top" rowspan="1" colspan="1">&#x02212;7.2 (&#x02212;12.8, &#x02212;1.5)<xref ref-type="fn" rid="dom12954-note-0003">*</xref>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0199" valign="top" rowspan="1" colspan="1">Heart rate, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0004">a</xref> bpm</td><td align="left" id="dom12954-ent-0200" valign="top" rowspan="1" colspan="1">2.7 (&#x02212;0.0, 5.4)</td><td align="left" id="dom12954-ent-0201" valign="top" rowspan="1" colspan="1">&#x02212;0.2 (&#x02212;5.1, 4.7)</td><td align="left" id="dom12954-ent-0202" valign="top" rowspan="1" colspan="1">2.5 (&#x02212;1.7, 6.8)</td><td align="left" id="dom12954-ent-0203" valign="top" rowspan="1" colspan="1">0.5 (&#x02212;2.4, 3.4)</td><td align="left" id="dom12954-ent-0204" valign="top" rowspan="1" colspan="1">5.5 (0.5, 10.6)<xref ref-type="fn" rid="dom12954-note-0003">*</xref>
</td><td align="left" id="dom12954-ent-0205" valign="top" rowspan="1" colspan="1">6.1 (1.8, 10.3)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td></tr><tr><td colspan="7" align="left" style="padding-left:10%" id="dom12954-ent-0206" valign="top" rowspan="1">
<italic><bold>Serum lipids</bold></italic>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0207" valign="top" rowspan="1" colspan="1">Total cholesterol, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0004">a</xref> mmol/L</td><td align="left" id="dom12954-ent-0208" valign="top" rowspan="1" colspan="1">&#x02212;0.16 (&#x02212;0.42, 0.09)</td><td align="left" id="dom12954-ent-0209" valign="top" rowspan="1" colspan="1">&#x02212;0.13 (&#x02212;0.43, 0.18)</td><td align="left" id="dom12954-ent-0210" valign="top" rowspan="1" colspan="1">&#x02212;0.29 (&#x02212;0.57, &#x02212;0.01)<xref ref-type="fn" rid="dom12954-note-0003">*</xref>
</td><td align="left" id="dom12954-ent-0211" valign="top" rowspan="1" colspan="1">&#x02212;0.26 (&#x02212;0.53, 0.02)</td><td align="left" id="dom12954-ent-0212" valign="top" rowspan="1" colspan="1">&#x02212;0.07 (&#x02212;0.37, 0.24)</td><td align="left" id="dom12954-ent-0213" valign="top" rowspan="1" colspan="1">&#x02212;0.33 (&#x02212;0.60, &#x02212;0.05)<xref ref-type="fn" rid="dom12954-note-0003">*</xref>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0214" valign="top" rowspan="1" colspan="1">LDL cholesterol, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0004">a</xref> mmol/L</td><td align="left" id="dom12954-ent-0215" valign="top" rowspan="1" colspan="1">&#x02212;0.17 (&#x02212;0.38, 0.05)</td><td align="left" id="dom12954-ent-0216" valign="top" rowspan="1" colspan="1">&#x02212;0.17 (&#x02212;0.44, 0.10)</td><td align="left" id="dom12954-ent-0217" valign="top" rowspan="1" colspan="1">&#x02212;0.34 (&#x02212;0.58, &#x02212;0.09)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td><td align="left" id="dom12954-ent-0218" valign="top" rowspan="1" colspan="1">&#x02212;0.22 (&#x02212;0.44, 0.001)</td><td align="left" id="dom12954-ent-0219" valign="top" rowspan="1" colspan="1">&#x02212;0.13 (&#x02212;0.40, 0.14)</td><td align="left" id="dom12954-ent-0220" valign="top" rowspan="1" colspan="1">&#x02212;0.35 (&#x02212;0.59, &#x02212;0.11)<xref ref-type="fn" rid="dom12954-note-0003a">**</xref>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0221" valign="top" rowspan="1" colspan="1">HDL cholesterol, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0004">a</xref> mmol/L</td><td align="left" id="dom12954-ent-0222" valign="top" rowspan="1" colspan="1">0.01 (&#x02212;0.06, 0.09)</td><td align="left" id="dom12954-ent-0223" valign="top" rowspan="1" colspan="1">&#x02212;0.02 (&#x02212;0.13, 0.10)</td><td align="left" id="dom12954-ent-0224" valign="top" rowspan="1" colspan="1">&#x02212;0.004 (&#x02212;0.12, 0.11)</td><td align="left" id="dom12954-ent-0225" valign="top" rowspan="1" colspan="1">&#x02212;0.08 (&#x02212;0.16, 0.002)</td><td align="left" id="dom12954-ent-0226" valign="top" rowspan="1" colspan="1">0.10 (&#x02212;0.01, 0.21)</td><td align="left" id="dom12954-ent-0227" valign="top" rowspan="1" colspan="1">0.02 (&#x02212;0.09, 0.13)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0228" valign="top" rowspan="1" colspan="1">Triglycerides, adjusted mean change (95% CI),<xref ref-type="fn" rid="dom12954-note-0004">a</xref> mmol/L</td><td align="left" id="dom12954-ent-0229" valign="top" rowspan="1" colspan="1">&#x02212;0.10 (&#x02212;0.29, 0.10)</td><td align="left" id="dom12954-ent-0230" valign="top" rowspan="1" colspan="1">&#x02212;0.15 (&#x02212;0.39, 0.08)</td><td align="left" id="dom12954-ent-0231" valign="top" rowspan="1" colspan="1">&#x02212;0.25 (&#x02212;0.45, &#x02212;0.05)<xref ref-type="fn" rid="dom12954-note-0003">*</xref>
</td><td align="left" id="dom12954-ent-0232" valign="top" rowspan="1" colspan="1">&#x02212;0.003 (&#x02212;0.20, 0.20)</td><td align="left" id="dom12954-ent-0233" valign="top" rowspan="1" colspan="1">&#x02212;0.10 (&#x02212;0.33, 0.13)</td><td align="left" id="dom12954-ent-0234" valign="top" rowspan="1" colspan="1">&#x02212;0.10 (&#x02212;0.30, 0.09)</td></tr></tbody></table><table-wrap-foot><fn id="dom12954-note-0002"><p>Abbreviations: <styled-content style="fixed-case">BP</styled-content>, blood pressure; bpm, beats per minute; <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">FPG</styled-content>, fasting plasma glucose; <styled-content style="fixed-case">HbA1c</styled-content>, glycated haemoglobin; <styled-content style="fixed-case">HDL</styled-content>, high&#x02010;density lipoprotein; <styled-content style="fixed-case">IFG</styled-content>, impaired fasting glucose (defined as <styled-content style="fixed-case">FPG</styled-content> &#x02265;5.6&#x02009;mmol/L measured just before an <styled-content style="fixed-case">OGTT</styled-content> at the 24&#x02010;week visit); <styled-content style="fixed-case">IGT</styled-content>, impaired glucose tolerance (defined as a plasma glucose value &#x02265;7.8&#x02009;mmol/L measured 2&#x02009;hours after the start of an <styled-content style="fixed-case">OGTT</styled-content> at the 24&#x02010;week visit); <styled-content style="fixed-case">LDL</styled-content>, low&#x02010;density lipoprotein; <styled-content style="fixed-case">MRI</styled-content>, magnetic resonance imaging; <styled-content style="fixed-case">NA</styled-content>, not available; <styled-content style="fixed-case">OGTT</styled-content>, oral glucose tolerance test; 2&#x02010;h <styled-content style="fixed-case">PG</styled-content>, 2&#x02010;hour plasma glucose level measured 2&#x02009;hours after the start of the <styled-content style="fixed-case">OGTT</styled-content>; <styled-content style="fixed-case">QD</styled-content>, once daily; <styled-content style="fixed-case">QW</styled-content>, once weekly; <styled-content style="fixed-case">SAAT</styled-content>, subcutaneous abdominal adipose tissue; <styled-content style="fixed-case">SD</styled-content>, standard deviation; <styled-content style="fixed-case">VAAT</styled-content>, visceral abdominal adipose tissue.</p></fn><fn id="dom12954-note-0003"><label>*</label><p>
<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.05;</p></fn><fn id="dom12954-note-0003a"><label>**</label><p>
<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.01;</p></fn><fn id="dom12954-note-0003b"><label>***</label><p>
<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content>&#x02009;&#x0003c;&#x02009;.001 for change from <styled-content style="fixed-case">W</styled-content>eek 0 to <styled-content style="fixed-case">W</styled-content>eek 24.</p></fn><fn id="dom12954-note-0004"><label>a</label><p>
Data are expressed as mean changes and 95% <styled-content style="fixed-case">CIs</styled-content> derived from a mixed model for repeated measures adjusted for treatment, week, treatment&#x02010;by&#x02010;week, sex and baseline value.</p></fn><fn id="dom12954-note-0005"><label>b</label><p>
Data are expressed as mean changes and 95% <styled-content style="fixed-case">CIs</styled-content> derived from a mixed model for repeated measures adjusted for week, sex and baseline value.</p></fn><fn id="dom12954-note-0006"><label>c</label><p>
Defined as the subcutaneous fat positioned between the hip joint and up to the lower pole of the lungs.</p></fn><fn id="dom12954-note-0007"><label>d</label><p>
<styled-content style="italic-in-any-context"><styled-content style="fixed-case">P</styled-content></styled-content> value based on a paired <styled-content style="fixed-case">McNemar</styled-content> test.</p></fn><fn id="dom12954-note-0008"><label>e</label><p>
Values at 24 and 52&#x02009;weeks derived from urine collected during a 3&#x02010;hour <styled-content style="fixed-case">OGTT</styled-content>.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="dom12954-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Changes in body weight, body composition, abdominal adipose tissue, and <styled-content style="fixed-case">SBP</styled-content>. <styled-content style="fixed-case">A</styled-content>, <styled-content style="fixed-case">P</styled-content>rimary endpoint: adjusted mean change from week 0 in body weight (kg) at 24 and 52&#x02009;weeks. <styled-content style="fixed-case">B</styled-content>, <styled-content style="fixed-case">S</styled-content>econdary endpoint: adjusted mean percentage change from week 0 in body weight (%) at 24 and 52&#x02009;weeks. <styled-content style="fixed-case">C</styled-content>, <styled-content style="fixed-case">I</styled-content>ndividual participant trajectories of percent change in body weight over 52&#x02009;weeks in dapagliflozin/exenatide&#x02010;treated participants (*although 9 participants discontinued <styled-content style="fixed-case">DAPA</styled-content>&#x02009;+&#x02009;<styled-content style="fixed-case">ExQW</styled-content>, 1 of these participants attended the final visit for weight measurement). <styled-content style="fixed-case">D</styled-content>, <styled-content style="fixed-case">C</styled-content>orresponding trajectories in placebo&#x02010;treated participants. <styled-content style="fixed-case">E</styled-content>, <styled-content style="fixed-case">A</styled-content>djusted mean change from week 0 in total lean and total adipose tissue volume and in visceral subcutaneous adipose tissue volume at 24 and 52&#x02009;weeks among participants continuing on <styled-content style="fixed-case">DAPA</styled-content>&#x02009;+&#x02009;<styled-content style="fixed-case">ExQW</styled-content> throughout the study. <styled-content style="fixed-case">F</styled-content>, <styled-content style="fixed-case">A</styled-content>djusted mean change from week 0 in <styled-content style="fixed-case">SBP</styled-content> (<styled-content style="fixed-case">mm Hg</styled-content>) over 24 and 52&#x02009;weeks. Analyses in panels <styled-content style="fixed-case">A</styled-content>, <styled-content style="fixed-case">B</styled-content>, <styled-content style="fixed-case">E</styled-content> and <styled-content style="fixed-case">F</styled-content> employed mixed models for repeated measures of change or percentage change from baseline adjusted for treatment, week, treatment&#x02010;by&#x02010;week, sex and baseline value. <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">DAPA</styled-content>&#x02009;+&#x02009;<styled-content style="fixed-case">ExQW</styled-content>, dapagliflozin 10&#x02009;mg once daily plus exenatide 2&#x02009;mg once weekly; <styled-content style="fixed-case">PBO</styled-content>, placebo; <styled-content style="fixed-case">SBP</styled-content>, systolic blood pressure; w, week(s)</p></caption><graphic id="nlm-graphic-3" xlink:href="DOM-19-1276-g002"/></fig></sec><sec id="dom12954-sec-0017"><label>3.2.2</label><title>Waist circumference</title><p id="dom12954-para-0026">Waist circumference was significantly reduced at 52&#x02009;weeks for both the DAPA&#x02009;+&#x02009;ExQW and PBO&#x02009;&#x02192;&#x02009;DAPA&#x02009;+&#x02009;ExQW groups (&#x02212;7.3 and &#x02212;6.7&#x02009;cm, respectively). A similar finding was evident for waist&#x02010;to&#x02010;hip ratio (Table <xref rid="dom12954-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec><sec id="dom12954-sec-0018"><label>3.2.3</label><title>
<styled-content style="fixed-case">MRI</styled-content> of body composition</title><p id="dom12954-para-0027">Among participants continuing on DAPA&#x02009;+&#x02009;ExQW, total adipose tissue reduction achieved at 24&#x02009;weeks (&#x02212;3.8&#x02009;L) was sustained at 52&#x02009;weeks (&#x02212;5.3&#x02009;L), with some additional total adipose tissue loss from 24 to 52&#x02009;weeks (&#x02212;1.5&#x02009;L) that did not reach statistical significance (Table <xref rid="dom12954-tbl-0001" ref-type="table-wrap">1</xref>, Figure <xref rid="dom12954-fig-0002" ref-type="fig">2</xref>E). Similar findings were observed for abdominal visceral and subcutaneous adipose tissue volumes (Table <xref rid="dom12954-tbl-0001" ref-type="table-wrap">1</xref>, Figure <xref rid="dom12954-fig-0002" ref-type="fig">2</xref>E). Numeric reductions in liver fat percent units in participants continuing on DAPA&#x02009;+&#x02009;ExQW did not reach statistical significance at either 24 or 52&#x02009;weeks (Table <xref rid="dom12954-tbl-0001" ref-type="table-wrap">1</xref>). Mean (Figure <xref rid="dom12954-supitem-0001" ref-type="supplementary-material">S2</xref>A in File <xref rid="dom12954-supitem-0001" ref-type="supplementary-material">S1</xref>) and individual trajectories of change in liver fat percent units for DAPA&#x02009;+&#x02009;ExQW (Figure <xref rid="dom12954-supitem-0001" ref-type="supplementary-material">S2</xref>B in File <xref rid="dom12954-supitem-0001" ref-type="supplementary-material">S1</xref>) and PBO (Figure <xref rid="dom12954-supitem-0001" ref-type="supplementary-material">S2</xref>C in File S1) are presented in Figure <xref rid="dom12954-supitem-0001" ref-type="supplementary-material">S2</xref> of File <xref rid="dom12954-supitem-0001" ref-type="supplementary-material">S1</xref>.</p></sec><sec id="dom12954-sec-0019"><label>3.2.4</label><title>Glycaemic variables</title><p id="dom12954-para-0028">Among participants continuing on DAPA&#x02009;+&#x02009;ExQW, reduction in HbA1c achieved at 24&#x02009;weeks (&#x02212;3.9&#x02009;mmol/mol [&#x02212;0.36%]) was sustained at 52&#x02009;weeks (&#x02212;3.1&#x02009;mmol/mol [&#x02212;0.28%]) (Table <xref rid="dom12954-tbl-0001" ref-type="table-wrap">1</xref>, Figure <xref rid="dom12954-fig-0003" ref-type="fig">3</xref>A). In the PBO&#x02009;&#x02192;&#x02009;DAPA&#x02009;+&#x02009;ExQW group, HbA1c reduction at 52&#x02009;weeks (&#x02212;3.2&#x02009;mmol/mol [&#x02212;0.29%]) was comparable to that in the continuing DAPA&#x02009;+&#x02009;ExQW group during the first 24&#x02009;weeks of therapy (&#x02212;3.9&#x02009;mmol/mol [&#x02212;0.36%]). Similar results were obtained for changes in FPG (Table <xref rid="dom12954-tbl-0001" ref-type="table-wrap">1</xref>, Figure <xref rid="dom12954-fig-0003" ref-type="fig">3</xref>B). Of note, among participants receiving PBO from 0 to 24&#x02009;weeks, FPG significantly rose (+0.25&#x02009;mmol/L vs baseline) and, upon switch to active treatment, significantly fell at 52&#x02009;weeks (&#x02212;0.25&#x02009;mmol/L vs baseline) (Table <xref rid="dom12954-tbl-0001" ref-type="table-wrap">1</xref>, Figure <xref rid="dom12954-fig-0003" ref-type="fig">3</xref>B).</p><fig fig-type="Figure" xml:lang="en" id="dom12954-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Changes in glycaemic endpoints and prediabetes. <styled-content style="fixed-case">A</styled-content>, <styled-content style="fixed-case">A</styled-content>djusted mean change from week 0 in <styled-content style="fixed-case">HbA1c</styled-content> (mmol/mol) over 24 and 52&#x02009;weeks. <styled-content style="fixed-case">B</styled-content>, <styled-content style="fixed-case">A</styled-content>djusted mean change from week 0 in <styled-content style="fixed-case">FPG</styled-content> (mmol/L) after 24 and 52&#x02009;weeks. <styled-content style="fixed-case">C</styled-content>, <styled-content style="fixed-case">P</styled-content>roportion of participants in the original DAPA&#x02009;+&#x02009;ExQW group with impaired fasting glucose or impaired glucose tolerance at screening and after 24 and 52&#x02009;weeks. Analyses in panels <styled-content style="fixed-case">A</styled-content> and <styled-content style="fixed-case">B</styled-content> employed mixed models for repeated measures of change or percentage change from baseline adjusted for treatment, week, treatment&#x02010;by&#x02010;week, sex and baseline value. <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">DAPA</styled-content>&#x02009;+&#x02009;<styled-content style="fixed-case">ExQW</styled-content>, dapagliflozin 10&#x02009;mg once daily plus exenatide 2&#x02009;mg once weekly; <styled-content style="fixed-case">FPG</styled-content>, fasting plasma glucose; <styled-content style="fixed-case">HbA1c</styled-content>, glycated haemoglobin; <styled-content style="fixed-case">PBO</styled-content>, placebo; w, week(s). *Two participants for whom values were missing. <sup>&#x02020;</sup>Eight participants for whom values were missing. <sup>&#x02021;</sup>Ten participants for whom values were missing</p></caption><graphic id="nlm-graphic-5" xlink:href="DOM-19-1276-g003"/></fig><p id="dom12954-para-0029">As previously reported,<xref rid="dom12954-bib-0020" ref-type="ref">20</xref> OGTT&#x02010;derived measures showed that 73.5% of participants had evidence of abnormal glucose metabolism at baseline; these parameters improved during treatment with DAPA&#x02009;+&#x02009;ExQW but not with PBO. Among participants continuing on DAPA&#x02009;+&#x02009;ExQW, these reductions in 2&#x02010;hour PG (&#x02212;1.9&#x02009;mmol/L), IFG (64%&#x02009;&#x02192;&#x02009;34.8%), IGT (48%&#x02009;&#x02192;&#x02009;17.4%) and prediabetes (68%&#x02009;&#x02192;&#x02009;34.8%) at 24&#x02009;weeks were sustained at 52&#x02009;weeks (&#x02212;2.2&#x02009;mmol/L, 35.3%, 13.3% and 35.3%, respectively) (Table <xref rid="dom12954-tbl-0001" ref-type="table-wrap">1</xref>, Figure <xref rid="dom12954-fig-0003" ref-type="fig">3</xref>C).</p></sec><sec id="dom12954-sec-0020"><label>3.2.5</label><title>Vital signs</title><p id="dom12954-para-0030">In this predominantly normotensive population at baseline (mean baseline SBP, 134&#x02009;mm Hg),<xref rid="dom12954-bib-0020" ref-type="ref">20</xref> participants continuing on DAPA&#x02009;+&#x02009;ExQW showed a significant reduction in SBP at 24&#x02009;weeks (&#x02212;9.8&#x02009;mm Hg), which was sustained at 52&#x02009;weeks (&#x02212;12.0&#x02009;mm Hg) (Table <xref rid="dom12954-tbl-0001" ref-type="table-wrap">1</xref>, Figure <xref rid="dom12954-fig-0002" ref-type="fig">2</xref>F). No changes in DBP were observed for either treatment group. Heart rate was unchanged in the continued DAPA&#x02009;+&#x02009;ExQW group, but increased in the PBO&#x02009;&#x02192;&#x02009;DAPA&#x02009;+&#x02009;ExQW group from 0 to 52&#x02009;weeks (Table <xref rid="dom12954-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec><sec id="dom12954-sec-0021"><label>3.2.6</label><title>Fasting serum lipids</title><p id="dom12954-para-0031">No significant changes in high&#x02010;density lipoprotein cholesterol were observed in participants in either treatment group. Low&#x02010;density lipoprotein cholesterol decreased significantly from 0 to 52&#x02009;weeks in both groups, and triglycerides decreased significantly from 0 to 52&#x02009;weeks in the continued DAPA&#x02009;+&#x02009;ExQW group (Table <xref rid="dom12954-tbl-0001" ref-type="table-wrap">1</xref>).</p></sec></sec><sec id="dom12954-sec-0022"><label>3.3</label><title>Safety and tolerability</title><p id="dom12954-para-0032">All participants in both groups reported at least 1 AE by week 52 (Table <xref rid="dom12954-tbl-0002" ref-type="table-wrap">2</xref>). In the continued DAPA&#x02009;+&#x02009;ExQW group, serious AEs occurred in 1 participant during the 0&#x02010; to 24&#x02010;week period (injury) and in 2 participants during the 24&#x02010; to 52&#x02010;week period (colon adenocarcinoma/gastrointestinal haemorrhage, angioedema; both led to discontinuation). In the PBO&#x02009;&#x02192;&#x02009;DAPA&#x02009;+&#x02009;ExQW group, a serious AE occurred in 1 participant during the 0&#x02010; to 24&#x02010;week period (dyspnoea/fatigue; this also led to discontinuation) and none thereafter. AEs leading to treatment discontinuation occurred in a further 2 participants in the continued DAPA&#x02009;+&#x02009;ExQW group during the 0&#x02010; to 24&#x02010;week period (abdominal pain, pruritus) and in 2 participants during the 24&#x02010; to 52&#x02010;week period (dizziness/nausea/fatigue, eye allergy). In the PBO&#x02009;&#x02192;&#x02009;DAPA&#x02009;+&#x02009;ExQW group, a further 2 participants discontinued during the 0&#x02010; to 24&#x02010;week period (vasculitis/skin ulcer, malaise) and none thereafter.</p><table-wrap id="dom12954-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Overview of <styled-content style="fixed-case">AEs</styled-content> and key laboratory changes occurring from 0 to 24, 24 to 52 and 0 to 52&#x02009;weeks (safety analysis set)</p></caption><table frame="hsides" rules="groups"><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><col width="1*" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th style="border-bottom:solid 1px #000000" align="left" id="dom12954-ent-0235" valign="bottom" rowspan="1" colspan="1"/><th colspan="2" align="left" id="dom12954-ent-0236" valign="bottom" rowspan="1">Weeks 0 to 24</th><th colspan="2" align="left" id="dom12954-ent-0237" valign="bottom" rowspan="1">Weeks 24 to 52</th><th colspan="2" align="left" id="dom12954-ent-0238" valign="bottom" rowspan="1">Weeks 0 to 52</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" id="dom12954-ent-0239" valign="bottom" rowspan="1" colspan="1"/><th align="center" id="dom12954-ent-0240" valign="bottom" rowspan="1" colspan="1">DAPA&#x02009;+&#x02009;ExQW (n&#x02009;=&#x02009;25)</th><th align="center" id="dom12954-ent-0241" valign="bottom" rowspan="1" colspan="1">PBO (n&#x02009;=&#x02009;25)</th><th align="center" id="dom12954-ent-0242" valign="bottom" rowspan="1" colspan="1">DAPA&#x02009;+&#x02009;ExQW (n&#x02009;=&#x02009;25)</th><th align="center" id="dom12954-ent-0243" valign="bottom" rowspan="1" colspan="1">PBO&#x02009;&#x02192;&#x02009;DAPA&#x02009;+&#x02009;ExQW (n&#x02009;=&#x02009;25)</th><th align="center" id="dom12954-ent-0244" valign="bottom" rowspan="1" colspan="1">DAPA&#x02009;+&#x02009;ExQW (n&#x02009;=&#x02009;25)</th><th align="center" id="dom12954-ent-0245" valign="bottom" rowspan="1" colspan="1">PBO&#x02009;&#x02192;&#x02009;DAPA&#x02009;+&#x02009;ExQW (n&#x02009;=&#x02009;25)</th></tr></thead><tbody valign="top"><tr><td align="left" id="dom12954-ent-0246" valign="top" rowspan="1" colspan="1">
<bold>Any AE</bold>
</td><td align="char" char="(" id="dom12954-ent-0247" valign="top" rowspan="1" colspan="1">25 (100.0)</td><td align="char" char="(" id="dom12954-ent-0248" valign="top" rowspan="1" colspan="1">25 (100.0)</td><td align="char" char="(" id="dom12954-ent-0249" valign="top" rowspan="1" colspan="1">17 (68.0)</td><td align="char" char="(" id="dom12954-ent-0250" valign="top" rowspan="1" colspan="1">16 (64.0)</td><td align="char" char="(" id="dom12954-ent-0251" valign="top" rowspan="1" colspan="1">25 (100.0)</td><td align="char" char="(" id="dom12954-ent-0252" valign="top" rowspan="1" colspan="1">25 (100.0)</td></tr><tr><td align="left" id="dom12954-ent-0253" valign="top" rowspan="1" colspan="1">
<bold>Any serious AE</bold>
<xref ref-type="fn" rid="dom12954-note-0010">a</xref>
</td><td align="char" char="(" id="dom12954-ent-0254" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0255" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0256" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0257" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0258" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0259" valign="top" rowspan="1" colspan="1">1 (4.0)</td></tr><tr><td align="left" id="dom12954-ent-0260" valign="top" rowspan="1" colspan="1">
<bold>Treatment&#x02010;related AEs</bold>
</td><td align="char" char="(" id="dom12954-ent-0261" valign="top" rowspan="1" colspan="1">5 (20.0)</td><td align="char" char="(" id="dom12954-ent-0262" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0263" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0264" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0265" valign="top" rowspan="1" colspan="1">5 (20.0)</td><td align="char" char="(" id="dom12954-ent-0266" valign="top" rowspan="1" colspan="1">3 (12.0)</td></tr><tr><td align="left" id="dom12954-ent-0267" valign="top" rowspan="1" colspan="1">
<bold>AEs leading to study discontinuation</bold>
<xref ref-type="fn" rid="dom12954-note-0011">b</xref>
</td><td align="char" char="(" id="dom12954-ent-0268" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0269" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0270" valign="top" rowspan="1" colspan="1">4 (16.0)</td><td align="char" char="(" id="dom12954-ent-0271" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0272" valign="top" rowspan="1" colspan="1">6 (24.0)</td><td align="char" char="(" id="dom12954-ent-0273" valign="top" rowspan="1" colspan="1">4 (16.0)</td></tr><tr><td align="left" id="dom12954-ent-0274" valign="top" rowspan="1" colspan="1">
<bold>Deaths</bold>
</td><td align="char" char="(" id="dom12954-ent-0275" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0276" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0277" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0278" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0279" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0280" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td colspan="7" align="left" id="dom12954-ent-0281" valign="top" rowspan="1">
<bold>Most common AEs occurring in &#x02265;20% in any group</bold>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0282" valign="top" rowspan="1" colspan="1">Nasopharyngitis</td><td align="char" char="(" id="dom12954-ent-0283" valign="top" rowspan="1" colspan="1">9 (36.0)</td><td align="char" char="(" id="dom12954-ent-0284" valign="top" rowspan="1" colspan="1">4 (16.0)</td><td align="char" char="(" id="dom12954-ent-0285" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0286" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0287" valign="top" rowspan="1" colspan="1">9 (36.0)</td><td align="char" char="(" id="dom12954-ent-0288" valign="top" rowspan="1" colspan="1">4 (16.0)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0289" valign="top" rowspan="1" colspan="1">Decreased appetite</td><td align="char" char="(" id="dom12954-ent-0290" valign="top" rowspan="1" colspan="1">8 (32.0)</td><td align="char" char="(" id="dom12954-ent-0291" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0292" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0293" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0294" valign="top" rowspan="1" colspan="1">9 (36.0)</td><td align="char" char="(" id="dom12954-ent-0295" valign="top" rowspan="1" colspan="1">3 (12.0)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0296" valign="top" rowspan="1" colspan="1">Dizziness</td><td align="char" char="(" id="dom12954-ent-0297" valign="top" rowspan="1" colspan="1">5 (20.0)</td><td align="char" char="(" id="dom12954-ent-0298" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0299" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0300" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0301" valign="top" rowspan="1" colspan="1">7 (28.0)</td><td align="char" char="(" id="dom12954-ent-0302" valign="top" rowspan="1" colspan="1">4 (16.0)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0303" valign="top" rowspan="1" colspan="1">Headache</td><td align="char" char="(" id="dom12954-ent-0304" valign="top" rowspan="1" colspan="1">8 (32.0)</td><td align="char" char="(" id="dom12954-ent-0305" valign="top" rowspan="1" colspan="1">4 (16.0)</td><td align="char" char="(" id="dom12954-ent-0306" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0307" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0308" valign="top" rowspan="1" colspan="1">8 (32.0)</td><td align="char" char="(" id="dom12954-ent-0309" valign="top" rowspan="1" colspan="1">4 (16.0)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0310" valign="top" rowspan="1" colspan="1">Nausea</td><td align="char" char="(" id="dom12954-ent-0311" valign="top" rowspan="1" colspan="1">7 (28.0)</td><td align="char" char="(" id="dom12954-ent-0312" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0313" valign="top" rowspan="1" colspan="1">5 (20.0)</td><td align="char" char="(" id="dom12954-ent-0314" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0315" valign="top" rowspan="1" colspan="1">9 (36.0)</td><td align="char" char="(" id="dom12954-ent-0316" valign="top" rowspan="1" colspan="1">4 (16.0)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0317" valign="top" rowspan="1" colspan="1">Pollakiuria</td><td align="char" char="(" id="dom12954-ent-0318" valign="top" rowspan="1" colspan="1">5 (20.0)</td><td align="char" char="(" id="dom12954-ent-0319" valign="top" rowspan="1" colspan="1">5 (20.0)</td><td align="char" char="(" id="dom12954-ent-0320" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0321" valign="top" rowspan="1" colspan="1">6 (24.0)</td><td align="char" char="(" id="dom12954-ent-0322" valign="top" rowspan="1" colspan="1">6 (24.0)</td><td align="char" char="(" id="dom12954-ent-0323" valign="top" rowspan="1" colspan="1">11 (44.0)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0324" valign="top" rowspan="1" colspan="1">Fatigue</td><td align="char" char="(" id="dom12954-ent-0325" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0326" valign="top" rowspan="1" colspan="1">6 (24.0)</td><td align="char" char="(" id="dom12954-ent-0327" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0328" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0329" valign="top" rowspan="1" colspan="1">4 (16.0)</td><td align="char" char="(" id="dom12954-ent-0330" valign="top" rowspan="1" colspan="1">7 (28.0)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0331" valign="top" rowspan="1" colspan="1">Injection&#x02010;site mass</td><td align="char" char="(" id="dom12954-ent-0332" valign="top" rowspan="1" colspan="1">7 (28.0)</td><td align="char" char="(" id="dom12954-ent-0333" valign="top" rowspan="1" colspan="1">5 (20.0)</td><td align="char" char="(" id="dom12954-ent-0334" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0335" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0336" valign="top" rowspan="1" colspan="1">7 (28.0)</td><td align="char" char="(" id="dom12954-ent-0337" valign="top" rowspan="1" colspan="1">6 (24.0)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0338" valign="top" rowspan="1" colspan="1">Injection&#x02010;site pruritus</td><td align="char" char="(" id="dom12954-ent-0339" valign="top" rowspan="1" colspan="1">7 (28.0)</td><td align="char" char="(" id="dom12954-ent-0340" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0341" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0342" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0343" valign="top" rowspan="1" colspan="1">7 (28.0)</td><td align="char" char="(" id="dom12954-ent-0344" valign="top" rowspan="1" colspan="1">2 (8.0)</td></tr><tr><td colspan="7" align="left" id="dom12954-ent-0345" valign="top" rowspan="1">
<bold>AEs of special interest</bold>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0346" valign="top" rowspan="1" colspan="1">Urinary tract infection<xref ref-type="fn" rid="dom12954-note-0012">c</xref>
</td><td align="char" char="(" id="dom12954-ent-0347" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0348" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0349" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0350" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0351" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0352" valign="top" rowspan="1" colspan="1">1 (4.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0353" valign="top" rowspan="1" colspan="1">Acute pyelonephritis</td><td align="char" char="(" id="dom12954-ent-0354" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0355" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0356" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0357" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0358" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0359" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0360" valign="top" rowspan="1" colspan="1">Urinary tract infection</td><td align="char" char="(" id="dom12954-ent-0361" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0362" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0363" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0364" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0365" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0366" valign="top" rowspan="1" colspan="1">1 (4.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0367" valign="top" rowspan="1" colspan="1">Fungal urinary tract infection</td><td align="char" char="(" id="dom12954-ent-0368" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0369" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0370" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0371" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0372" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0373" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0374" valign="top" rowspan="1" colspan="1">Genital infection<xref ref-type="fn" rid="dom12954-note-0012">c</xref>
</td><td align="char" char="(" id="dom12954-ent-0375" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0376" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0377" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0378" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0379" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0380" valign="top" rowspan="1" colspan="1">1 (4.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0381" valign="top" rowspan="1" colspan="1">Fungal</td><td align="char" char="(" id="dom12954-ent-0382" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0383" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0384" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0385" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0386" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0387" valign="top" rowspan="1" colspan="1">1 (4.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0388" valign="top" rowspan="1" colspan="1">Vaginal</td><td align="char" char="(" id="dom12954-ent-0389" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0390" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0391" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0392" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0393" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0394" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0395" valign="top" rowspan="1" colspan="1">Volume reduction<xref ref-type="fn" rid="dom12954-note-0012">c</xref>
</td><td align="char" char="(" id="dom12954-ent-0396" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0397" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0398" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0399" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0400" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0401" valign="top" rowspan="1" colspan="1">1 (4.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0402" valign="top" rowspan="1" colspan="1">Hypotension</td><td align="char" char="(" id="dom12954-ent-0403" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0404" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0405" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0406" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0407" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0408" valign="top" rowspan="1" colspan="1">1 (4.0)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0409" valign="top" rowspan="1" colspan="1">Renal impairment/failure<xref ref-type="fn" rid="dom12954-note-0012">c</xref>
</td><td align="char" char="(" id="dom12954-ent-0410" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0411" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0412" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0413" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0414" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0415" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0416" valign="top" rowspan="1" colspan="1">Gastrointestinal symptoms<xref ref-type="fn" rid="dom12954-note-0012">c</xref>
</td><td align="char" char="(" id="dom12954-ent-0417" valign="top" rowspan="1" colspan="1">16 (64.0)</td><td align="char" char="(" id="dom12954-ent-0418" valign="top" rowspan="1" colspan="1">11 (44.0)</td><td align="char" char="(" id="dom12954-ent-0419" valign="top" rowspan="1" colspan="1">6 (24.0)</td><td align="char" char="(" id="dom12954-ent-0420" valign="top" rowspan="1" colspan="1">6 (24.0)</td><td align="char" char="(" id="dom12954-ent-0421" valign="top" rowspan="1" colspan="1">17 (68.0)</td><td align="char" char="(" id="dom12954-ent-0422" valign="top" rowspan="1" colspan="1">14 (56.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0423" valign="top" rowspan="1" colspan="1">Nausea</td><td align="char" char="(" id="dom12954-ent-0424" valign="top" rowspan="1" colspan="1">7 (28.0)</td><td align="char" char="(" id="dom12954-ent-0425" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0426" valign="top" rowspan="1" colspan="1">5 (20.0)</td><td align="char" char="(" id="dom12954-ent-0427" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0428" valign="top" rowspan="1" colspan="1">9 (36.0)</td><td align="char" char="(" id="dom12954-ent-0429" valign="top" rowspan="1" colspan="1">4 (16.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0430" valign="top" rowspan="1" colspan="1">Abdominal pain</td><td align="char" char="(" id="dom12954-ent-0431" valign="top" rowspan="1" colspan="1">4 (16.0)</td><td align="char" char="(" id="dom12954-ent-0432" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0433" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0434" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0435" valign="top" rowspan="1" colspan="1">4 (16.0)</td><td align="char" char="(" id="dom12954-ent-0436" valign="top" rowspan="1" colspan="1">4 (16.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0437" valign="top" rowspan="1" colspan="1">Diarrhoea</td><td align="char" char="(" id="dom12954-ent-0438" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0439" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0440" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0441" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0442" valign="top" rowspan="1" colspan="1">4 (16.0)</td><td align="char" char="(" id="dom12954-ent-0443" valign="top" rowspan="1" colspan="1">4 (16.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0444" valign="top" rowspan="1" colspan="1">Abdominal distension</td><td align="char" char="(" id="dom12954-ent-0445" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0446" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0447" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0448" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0449" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0450" valign="top" rowspan="1" colspan="1">2 (8.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0451" valign="top" rowspan="1" colspan="1">Vomiting</td><td align="char" char="(" id="dom12954-ent-0452" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0453" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0454" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0455" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0456" valign="top" rowspan="1" colspan="1">4 (16.0)</td><td align="char" char="(" id="dom12954-ent-0457" valign="top" rowspan="1" colspan="1">2 (8.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0458" valign="top" rowspan="1" colspan="1">Gastroesophageal reflux</td><td align="char" char="(" id="dom12954-ent-0459" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0460" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0461" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0462" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0463" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0464" valign="top" rowspan="1" colspan="1">2 (8.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0465" valign="top" rowspan="1" colspan="1">Constipation</td><td align="char" char="(" id="dom12954-ent-0466" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0467" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0468" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0469" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0470" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0471" valign="top" rowspan="1" colspan="1">2 (8.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0472" valign="top" rowspan="1" colspan="1">Dyspepsia</td><td align="char" char="(" id="dom12954-ent-0473" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0474" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0475" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0476" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0477" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0478" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0479" valign="top" rowspan="1" colspan="1">Injection&#x02010;site reactions<xref ref-type="fn" rid="dom12954-note-0012">c</xref>
</td><td align="char" char="(" id="dom12954-ent-0480" valign="top" rowspan="1" colspan="1">11 (44.0)</td><td align="char" char="(" id="dom12954-ent-0481" valign="top" rowspan="1" colspan="1">8 (32.0)</td><td align="char" char="(" id="dom12954-ent-0482" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0483" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0484" valign="top" rowspan="1" colspan="1">11 (44.0)</td><td align="char" char="(" id="dom12954-ent-0485" valign="top" rowspan="1" colspan="1">9 (36.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0486" valign="top" rowspan="1" colspan="1">Injection&#x02010;site mass</td><td align="char" char="(" id="dom12954-ent-0487" valign="top" rowspan="1" colspan="1">7 (28.0)</td><td align="char" char="(" id="dom12954-ent-0488" valign="top" rowspan="1" colspan="1">5 (20.0)</td><td align="char" char="(" id="dom12954-ent-0489" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0490" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0491" valign="top" rowspan="1" colspan="1">7 (28.0)</td><td align="char" char="(" id="dom12954-ent-0492" valign="top" rowspan="1" colspan="1">6 (24.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0493" valign="top" rowspan="1" colspan="1">Injection&#x02010;site pruritus</td><td align="char" char="(" id="dom12954-ent-0494" valign="top" rowspan="1" colspan="1">7 (28.0)</td><td align="char" char="(" id="dom12954-ent-0495" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0496" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0497" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0498" valign="top" rowspan="1" colspan="1">7 (28.0)</td><td align="char" char="(" id="dom12954-ent-0499" valign="top" rowspan="1" colspan="1">2 (8.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0500" valign="top" rowspan="1" colspan="1">Injection&#x02010;site erythema</td><td align="char" char="(" id="dom12954-ent-0501" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0502" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0503" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0504" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0505" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0506" valign="top" rowspan="1" colspan="1">1 (4.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0507" valign="top" rowspan="1" colspan="1">Injection&#x02010;site nodule</td><td align="char" char="(" id="dom12954-ent-0508" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0509" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0510" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0511" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0512" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0513" valign="top" rowspan="1" colspan="1">1 (4.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0514" valign="top" rowspan="1" colspan="1">Injection&#x02010;site swelling</td><td align="char" char="(" id="dom12954-ent-0515" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0516" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0517" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0518" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0519" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0520" valign="top" rowspan="1" colspan="1">2 (8.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0521" valign="top" rowspan="1" colspan="1">Injection&#x02010;site pain</td><td align="char" char="(" id="dom12954-ent-0522" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0523" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0524" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0525" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0526" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0527" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0528" valign="top" rowspan="1" colspan="1">Injection&#x02010;site cyst</td><td align="char" char="(" id="dom12954-ent-0529" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0530" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0531" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0532" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0533" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0534" valign="top" rowspan="1" colspan="1">0 (0.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0535" valign="top" rowspan="1" colspan="1">Injection&#x02010;site rash</td><td align="char" char="(" id="dom12954-ent-0536" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0537" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0538" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0539" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0540" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0541" valign="top" rowspan="1" colspan="1">1 (4.0)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0542" valign="top" rowspan="1" colspan="1">Appetite changes</td><td align="char" char="(" id="dom12954-ent-0543" valign="top" rowspan="1" colspan="1">10 (40.0)</td><td align="char" char="(" id="dom12954-ent-0544" valign="top" rowspan="1" colspan="1">5 (20.0)</td><td align="char" char="(" id="dom12954-ent-0545" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0546" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0547" valign="top" rowspan="1" colspan="1">11 (44.0)</td><td align="char" char="(" id="dom12954-ent-0548" valign="top" rowspan="1" colspan="1">5 (20.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0549" valign="top" rowspan="1" colspan="1">Decreased appetite</td><td align="char" char="(" id="dom12954-ent-0550" valign="top" rowspan="1" colspan="1">8 (32.0)</td><td align="char" char="(" id="dom12954-ent-0551" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0552" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0553" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0554" valign="top" rowspan="1" colspan="1">9 (36.0)</td><td align="char" char="(" id="dom12954-ent-0555" valign="top" rowspan="1" colspan="1">3 (12.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0556" valign="top" rowspan="1" colspan="1">Increased appetite</td><td align="char" char="(" id="dom12954-ent-0557" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0558" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0559" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0560" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0561" valign="top" rowspan="1" colspan="1">2 (8.0)</td><td align="char" char="(" id="dom12954-ent-0562" valign="top" rowspan="1" colspan="1">1 (4.0)</td></tr><tr><td align="left" style="padding-left:15%" id="dom12954-ent-0563" valign="top" rowspan="1" colspan="1">Hunger</td><td align="char" char="(" id="dom12954-ent-0564" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0565" valign="top" rowspan="1" colspan="1">3 (12.0)</td><td align="char" char="(" id="dom12954-ent-0566" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0567" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="char" char="(" id="dom12954-ent-0568" valign="top" rowspan="1" colspan="1">1 (4.0)</td><td align="char" char="(" id="dom12954-ent-0569" valign="top" rowspan="1" colspan="1">3 (12.0)</td></tr><tr><td colspan="7" align="left" id="dom12954-ent-0570" valign="top" rowspan="1">
<bold>Key laboratory changes</bold>
</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0571" valign="top" rowspan="1" colspan="1">eGFR,<xref ref-type="fn" rid="dom12954-note-0013">d</xref> mean change (95% CI), mL/min/1.73&#x02009;m<sup>2</sup>
</td><td align="char" char="(" id="dom12954-ent-0572" valign="top" rowspan="1" colspan="1">&#x02212;1.77 (&#x02212;6.81, 3.27)</td><td align="char" char="(" id="dom12954-ent-0573" valign="top" rowspan="1" colspan="1">2.95 (&#x02212;1.20, 7.09)</td><td align="char" char="(" id="dom12954-ent-0574" valign="top" rowspan="1" colspan="1">&#x02212;0.29 (&#x02212;5.20, 4.62)</td><td align="char" char="(" id="dom12954-ent-0575" valign="top" rowspan="1" colspan="1">&#x02212;1.91 (&#x02212;6.33, 2.52)</td><td align="char" char="(" id="dom12954-ent-0576" valign="top" rowspan="1" colspan="1">1.34 (&#x02212;5.39, 8.07)</td><td align="char" char="(" id="dom12954-ent-0577" valign="top" rowspan="1" colspan="1">0.19 (&#x02212;3.15, 3.53)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0578" valign="top" rowspan="1" colspan="1">Serum creatinine, mean change (95% CI), &#x000b5;mol/L</td><td align="char" char="(" id="dom12954-ent-0579" valign="top" rowspan="1" colspan="1">1.61 (&#x02212;1.67, 4.89)</td><td align="char" char="(" id="dom12954-ent-0580" valign="top" rowspan="1" colspan="1">&#x02212;1.21 (&#x02212;4.08, 1.66)</td><td align="char" char="(" id="dom12954-ent-0581" valign="top" rowspan="1" colspan="1">0.38 (&#x02212;3.47, 4.22)</td><td align="char" char="(" id="dom12954-ent-0582" valign="top" rowspan="1" colspan="1">0.65 (&#x02212;2.78, 4.07)</td><td align="char" char="(" id="dom12954-ent-0583" valign="top" rowspan="1" colspan="1">&#x02212;0.25 (&#x02212;5.27, 4.77)</td><td align="char" char="(" id="dom12954-ent-0584" valign="top" rowspan="1" colspan="1">&#x02212;0.06 (&#x02212;2.47, 2.35)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0585" valign="top" rowspan="1" colspan="1">AST, mean change (95% CI), &#x000b5;kat/L</td><td align="char" char="(" id="dom12954-ent-0586" valign="top" rowspan="1" colspan="1">&#x02212;0.06 (&#x02212;0.12, 0.01)</td><td align="char" char="(" id="dom12954-ent-0587" valign="top" rowspan="1" colspan="1">&#x02212;0.09 (&#x02212;0.16, &#x02212;0.03)</td><td align="char" char="(" id="dom12954-ent-0588" valign="top" rowspan="1" colspan="1">0.01 (&#x02212;0.03, 0.05)</td><td align="char" char="(" id="dom12954-ent-0589" valign="top" rowspan="1" colspan="1">&#x02212;0.03 (&#x02212;0.07, 0.01)</td><td align="char" char="(" id="dom12954-ent-0590" valign="top" rowspan="1" colspan="1">&#x02212;0.04 (&#x02212;0.10, 0.03)</td><td align="char" char="(" id="dom12954-ent-0591" valign="top" rowspan="1" colspan="1">&#x02212;0.10 (&#x02212;0.15, &#x02212;0.05)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0592" valign="top" rowspan="1" colspan="1">ALT, mean change (95% CI), &#x000b5;kat/L</td><td align="char" char="(" id="dom12954-ent-0593" valign="top" rowspan="1" colspan="1">&#x02212;0.05 (&#x02212;0.15, 0.06)</td><td align="char" char="(" id="dom12954-ent-0594" valign="top" rowspan="1" colspan="1">&#x02212;0.13 (&#x02212;0.31, 0.05)</td><td align="char" char="(" id="dom12954-ent-0595" valign="top" rowspan="1" colspan="1">&#x02212;0.01 (&#x02212;0.09, 0.07)</td><td align="char" char="(" id="dom12954-ent-0596" valign="top" rowspan="1" colspan="1">&#x02212;0.08 (&#x02212;0.17, 0.02)</td><td align="char" char="(" id="dom12954-ent-0597" valign="top" rowspan="1" colspan="1">&#x02212;0.05 (&#x02212;0.14, 0.03)</td><td align="char" char="(" id="dom12954-ent-0598" valign="top" rowspan="1" colspan="1">&#x02212;0.14 (&#x02212;0.26, &#x02212;0.03)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0599" valign="top" rowspan="1" colspan="1">Haemoglobin, mean change (95% CI), g/L</td><td align="char" char="(" id="dom12954-ent-0600" valign="top" rowspan="1" colspan="1">3.4 (&#x02212;1.9, 8.7)</td><td align="char" char="(" id="dom12954-ent-0601" valign="top" rowspan="1" colspan="1">&#x02212;1.8 (&#x02212;5.2, 1.6)</td><td align="char" char="(" id="dom12954-ent-0602" valign="top" rowspan="1" colspan="1">&#x02212;1.8 (&#x02212;5.7, 2.1)</td><td align="char" char="(" id="dom12954-ent-0603" valign="top" rowspan="1" colspan="1">8.3 (5.0, 11.6)</td><td align="char" char="(" id="dom12954-ent-0604" valign="top" rowspan="1" colspan="1">0.3 (&#x02212;5.7, 6.3)</td><td align="char" char="(" id="dom12954-ent-0605" valign="top" rowspan="1" colspan="1">7.8 (3.5, 12.1)</td></tr><tr><td align="left" style="padding-left:10%" id="dom12954-ent-0606" valign="top" rowspan="1" colspan="1">hs&#x02010;CRP, mean change (95% CI), mg/dL</td><td align="char" char="(" id="dom12954-ent-0607" valign="top" rowspan="1" colspan="1">0.09 (&#x02212;0.87, 1.05)</td><td align="char" char="(" id="dom12954-ent-0608" valign="top" rowspan="1" colspan="1">&#x02212;0.81 (&#x02212;1.86, 0.24)</td><td align="char" char="(" id="dom12954-ent-0609" valign="top" rowspan="1" colspan="1">2.13 (&#x02212;1.41, 5.67)</td><td align="char" char="(" id="dom12954-ent-0610" valign="top" rowspan="1" colspan="1">&#x02212;0.13 (&#x02212;0.83, 0.58)</td><td align="char" char="(" id="dom12954-ent-0611" valign="top" rowspan="1" colspan="1">1.90 (&#x02212;1.71, 5.51)</td><td align="char" char="(" id="dom12954-ent-0612" valign="top" rowspan="1" colspan="1">&#x02212;0.75 (&#x02212;1.74, 0.25)</td></tr></tbody></table><table-wrap-foot><fn id="dom12954-note-0009"><p>Abbreviations: <styled-content style="fixed-case">AE</styled-content>, adverse event; <styled-content style="fixed-case">ALT</styled-content>, alanine aminotransferase; <styled-content style="fixed-case">AST</styled-content>, aspartate aminotransferase; <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">DAPA</styled-content>&#x02009;+&#x02009;<styled-content style="fixed-case">ExQW</styled-content>, dapagliflozin 10&#x02009;mg once daily plus exenatide 2&#x02009;mg once weekly; <styled-content style="fixed-case">eGFR</styled-content>, estimated glomerular filtration rate; hs&#x02010;<styled-content style="fixed-case">CRP</styled-content>; high&#x02010;sensitivity <styled-content style="fixed-case">C</styled-content>&#x02010;reactive protein; <styled-content style="fixed-case">PBO</styled-content>, placebo.</p></fn><fn id="dom12954-note-0010"><label>a</label><p>
Serious <styled-content style="fixed-case">AEs</styled-content> in the <styled-content style="fixed-case">DAPA</styled-content>&#x02009;+&#x02009;<styled-content style="fixed-case">ExQW</styled-content> group over 52&#x02009;weeks were hospitalization because of head trauma/injury, colon adenocarcinoma/gastrointestinal haemorrhage or angioedema.</p></fn><fn id="dom12954-note-0011"><label>b</label><p>
<styled-content style="fixed-case">AEs</styled-content> that led to treatment discontinuation in the <styled-content style="fixed-case">DAPA</styled-content>&#x02009;+&#x02009;<styled-content style="fixed-case">ExQW</styled-content> group over 52&#x02009;weeks were abdominal pain, injection&#x02010;site pruritus/mass, nausea, dizziness, fatigue and eye allergy.</p></fn><fn id="dom12954-note-0012"><label>c</label><p>
<styled-content style="fixed-case">AEs</styled-content> of urinary tract infections, genital infections, volume reduction, renal impairment/failure, gastrointestinal symptoms, and injection&#x02010;site reactions were coded using predefined lists of preferred terms (<styled-content style="fixed-case">M</styled-content>edical <styled-content style="fixed-case">D</styled-content>ictionary for <styled-content style="fixed-case">R</styled-content>egulatory <styled-content style="fixed-case">A</styled-content>ctivities [<styled-content style="fixed-case">MedDRA</styled-content>] version 18.0).</p></fn><fn id="dom12954-note-0013"><label>d</label><p>
Assessed using the <styled-content style="fixed-case">M</styled-content>odification of <styled-content style="fixed-case">D</styled-content>iet in <styled-content style="fixed-case">R</styled-content>enal <styled-content style="fixed-case">D</styled-content>isease formula.</p></fn></table-wrap-foot></table-wrap><p id="dom12954-para-0033">Genital infections and UTIs were rare during the 0&#x02010; to 24&#x02010;week period, with 2 and 1 participant(s) in the DAPA&#x02009;+&#x02009;ExQW and PBO&#x02009;&#x02192;&#x02009;DAPA&#x02009;+&#x02009;ExQW groups, respectively, reporting new episodes of genital infections during the 24&#x02010; to 52&#x02010;week period. No new UTIs occurred during the 24&#x02010; to 52&#x02010;week period. In the continuing DAPA&#x02009;+&#x02009;ExQW group, gastrointestinal symptoms and injection&#x02010;site disorders were reported less frequently during the 24&#x02010; to 52&#x02010;week period than during the 0&#x02010; to 24&#x02010;week period (Table <xref rid="dom12954-tbl-0002" ref-type="table-wrap">2</xref>).</p><p id="dom12954-para-0034">No participant experienced confirmed hypoglycaemia. One placebo&#x02010;treated participant was diagnosed with T2D at the 24&#x02010;week visit (according to American Diabetes Association PG and HbA1c criteria).<xref rid="dom12954-bib-0020" ref-type="ref">20</xref>
</p><p id="dom12954-para-0035">No participants receiving DAPA&#x02009;+&#x02009;ExQW experienced AEs of hypotension. No participants in either treatment group reported AEs potentially related to renal impairment or renal failure over 52&#x02009;weeks, and estimated glomerular filtration rate did not change significantly over time (Table <xref rid="dom12954-tbl-0002" ref-type="table-wrap">2</xref>). No other clinically significant changes in laboratory assessments were observed in either treatment group over 52&#x02009;weeks, apart from a small increase in haemoglobin at 52&#x02009;weeks in the PBO&#x02009;&#x02192;&#x02009;DAPA&#x02009;+&#x02009;ExQW group (Table <xref rid="dom12954-tbl-0002" ref-type="table-wrap">2</xref>). No AEs of pancreatitis or pancreatic cancer were reported.</p></sec></sec><sec id="dom12954-sec-0023"><label>4</label><title>DISCUSSION</title><p id="dom12954-para-0036">Achieving long&#x02010;term body weight loss to reduce cardiometabolic risk through lifestyle interventions alone is often immensely challenging. A high degree of motivation is required to achieve both initial body weight loss and, especially, to sustain this loss in the face of opposing influences, including physiological counter&#x02010;regulatory mechanisms seeking to regain body weight,<xref rid="dom12954-bib-0006" ref-type="ref">6</xref>, <xref rid="dom12954-bib-0022" ref-type="ref">22</xref> chronic hunger/food craving,<xref rid="dom12954-bib-0023" ref-type="ref">23</xref> and ongoing sociocultural pressures (eg, sedentary occupations) that impair consolidation of healthy lifestyles.<xref rid="dom12954-bib-0001" ref-type="ref">1</xref> Given the unmet need for novel pharmacotherapies to achieve and sustain body weight loss, and their established efficacy and safety in patients with T2D, the combination of an SGLT2 inhibitor (urinary caloric loss) and a GLP&#x02010;1RA (appetite suppression) may be an attractive option to assist obese individuals in reducing body weight as either standalone therapy (eg, when individuals must lose sufficient body weight to initiate an exercise programme)<xref rid="dom12954-bib-0024" ref-type="ref">24</xref> or an adjunct to lifestyle intervention.</p><p id="dom12954-para-0037">In this study of obese adults without diabetes who did not undergo a formal lifestyle intervention, a mean body weight loss of &#x02212;4.5&#x02009;kg after 24&#x02009;weeks of double&#x02010;blind treatment with DAPA&#x02009;+&#x02009;ExQW was sustained during an additional 28&#x02009;weeks of open&#x02010;label DAPA&#x02009;+&#x02009;ExQW, resulting in a total body weight loss of &#x02212;5.7&#x02009;kg, with 40.0% of participants achieving &#x02265;5% reduction in initial body weight at 52&#x02009;weeks. In addition, participants who switched from PBO to active treatment achieved reductions at 52&#x02009;weeks similar to those achieved in the continuing DAPA&#x02009;+&#x02009;ExQW group at 24&#x02009;weeks. MRI assessments indicated that the body weight reduction was largely accounted for by reduction in adipose tissue volume, which similarly involved subcutaneous and visceral depots.</p><p id="dom12954-para-0038">Although making cross&#x02010;study comparisons may be inaccurate because of differing populations and study designs, the degree of body weight loss with DAPA&#x02009;+&#x02009;ExQW appeared to be comparable to that achieved at 1&#x02009;year in obese individuals receiving approved pharmacotherapies for obesity. In a recent meta&#x02010;analysis, differences vs placebo in mean changes in body weight at 1&#x02009;year were &#x02212;2.63, &#x02212;3.25, &#x02212;4.95, &#x02212;5.24 and &#x02212;8.80&#x02009;kg with orlistat, lorcaserin, naltrexone/bupropion, liraglutide and phentermine/topiramate, respectively, and differences vs placebo in proportions achieving &#x02265;5% body weight loss at 1&#x02009;year were 23.0%, 24.4%, 32.1%, 36.3% and 49.3%, respectively.<xref rid="dom12954-bib-0025" ref-type="ref">25</xref> In the current study, placebo&#x02010;corrected changes in body weight and the proportion achieving body weight loss &#x02265;5% at 24&#x02009;weeks were &#x02212;4.5&#x02009;kg and 39.1%, respectively. Assuming that values at 52&#x02009;weeks would be similar to those at 24&#x02009;weeks had there been a continuing placebo arm, estimated placebo&#x02010;corrected changes at 52&#x02009;weeks and the proportion achieving body weight loss &#x02265;5% would be &#x02212;5.3&#x02009;kg and 40.0% (ITT percentage), respectively.</p><p id="dom12954-para-0039">However, the current study did not employ a formal lifestyle intervention in contrast to the studies included in the meta&#x02010;analysis by Khera et al<xref rid="dom12954-bib-0025" ref-type="ref">25</xref> all of which employed a diet and/or exercise co&#x02010;intervention. In addition, dose&#x02010;ranging studies with dapagliflozin, indicating that urinary glucose excretion increases at higher doses of dapagliflozin,<xref rid="dom12954-bib-0026" ref-type="ref">26</xref> and dose&#x02010;ranging studies of liraglutide,<xref rid="dom12954-bib-0027" ref-type="ref">27</xref> suggesting greater body weight loss with higher doses of a GLP&#x02010;1RA, suggest that increased doses of dapagliflozin and exenatide QW in combination could potentially achieve more substantial body weight loss. Thus, the full potential for weight reduction with this combination therapy is probably greater than described here, and needs to be determined in dose&#x02010;ranging studies that optimize the balance between efficacy and safety and in studies that include intensive lifestyle interventions.</p><p id="dom12954-para-0040">DAPA&#x02009;+&#x02009;ExQW improved multiple cardiometabolic risk factors as well as reduced body weight. Reductions in glycaemic measures and SBP at 24&#x02009;weeks were sustained at 52&#x02009;weeks; fasting low&#x02010;density lipoprotein cholesterol and triglycerides were also reduced by 52&#x02009;weeks. The reductions in glycaemic measures were similar to, and reductions in SBP were greater than, those achieved with liraglutide at the higher dose approved for obesity (3&#x02009;mg once daily)<xref rid="dom12954-bib-0028" ref-type="ref">28</xref>, <xref rid="dom12954-bib-0029" ref-type="ref">29</xref> and compared favourably with other approved therapies for obesity evaluated in participants without diabetes. Thus, reductions in HbA1c (&#x02212;3.1&#x02009;mmol/mol [&#x02212;0.28%]), FPG (&#x02212;0.31&#x02009;mmol/L) and SBP (&#x02212;12.0&#x02009;mm Hg) at 52&#x02009;weeks with DAPA&#x02009;+&#x02009;ExQW were greater than average reductions across 8 clinical trials evaluating orlistat 120&#x02009;mg (&#x02212;0.4&#x02009;mmol/mol [&#x02212;0.04%], &#x02212;0.14&#x02009;mmol/L and &#x02212;4.3&#x02009;mm Hg, respectively)<xref rid="dom12954-bib-0028" ref-type="ref">28</xref>, <xref rid="dom12954-bib-0030" ref-type="ref">30</xref>, <xref rid="dom12954-bib-0031" ref-type="ref">31</xref>, <xref rid="dom12954-bib-0032" ref-type="ref">32</xref>, <xref rid="dom12954-bib-0033" ref-type="ref">33</xref>, <xref rid="dom12954-bib-0034" ref-type="ref">34</xref>, <xref rid="dom12954-bib-0035" ref-type="ref">35</xref>, <xref rid="dom12954-bib-0036" ref-type="ref">36</xref>; across 2 clinical trials evaluating lorcaserin 10&#x02009;mg twice daily (&#x02013;1.3&#x02009;mmol/mol [&#x02212;0.12%], &#x02212;0.04&#x02009;mmol/L and &#x02212;1.7&#x02009;mm Hg, respectively)<xref rid="dom12954-bib-0037" ref-type="ref">37</xref>, <xref rid="dom12954-bib-0038" ref-type="ref">38</xref>; across 3 clinical trials evaluating naltrexone/bupropion 32/360&#x02009;mg in divided doses twice daily (not reported, &#x02212;0.16&#x02009;mmol/L and &#x02212;0.3&#x02009;mm Hg, respectively)<xref rid="dom12954-bib-0039" ref-type="ref">39</xref>, <xref rid="dom12954-bib-0040" ref-type="ref">40</xref>, <xref rid="dom12954-bib-0041" ref-type="ref">41</xref>; and in 1 clinical trial evaluating controlled&#x02010;release phentermine/topiramate 15/92&#x02009;mg once daily (not reported, &#x02212;0.03&#x02009;mmol/L and &#x02212;2.9&#x02009;mm Hg, respectively).<xref rid="dom12954-bib-0042" ref-type="ref">42</xref>
</p><p id="dom12954-para-0041">Both the SGLT2 inhibitor empagliflozin<xref rid="dom12954-bib-0043" ref-type="ref">43</xref>, <xref rid="dom12954-bib-0044" ref-type="ref">44</xref> and the GLP1&#x02010;RAs liraglutide and semaglutide<xref rid="dom12954-bib-0045" ref-type="ref">45</xref>, <xref rid="dom12954-bib-0046" ref-type="ref">46</xref> have recently been shown to substantially reduce fatal or nonfatal cardiovascular events in patients with T2D at high cardiovascular risk. In addition to cardiovascular meta&#x02010;analyses for dapagliflozin<xref rid="dom12954-bib-0047" ref-type="ref">47</xref> and exenatide,<xref rid="dom12954-bib-0048" ref-type="ref">48</xref> dedicated outcome trials are ongoing for both of these compounds (DECLARE TIMI&#x02010;58 [NCT01730534] and EXSCEL,<xref rid="dom12954-bib-0049" ref-type="ref">49</xref> respectively).</p><p id="dom12954-para-0042">The mechanisms leading to cardiovascular risk reduction are probably derived through a number of non&#x02010;glycaemic effects for both SGLT2 inhibitors<xref rid="dom12954-bib-0050" ref-type="ref">50</xref>, <xref rid="dom12954-bib-0051" ref-type="ref">51</xref>, <xref rid="dom12954-bib-0052" ref-type="ref">52</xref> and GLP&#x02010;1RAs.<xref rid="dom12954-bib-0053" ref-type="ref">53</xref>, <xref rid="dom12954-bib-0054" ref-type="ref">54</xref> In the current study among obese individuals without T2D, effects on SBP and body weight were similar to those with DAPA&#x02009;+&#x02009;ExQW among patients with T2D.<xref rid="dom12954-bib-0055" ref-type="ref">55</xref> However, it is unknown whether such effects will translate into reductions in risk for future cardiovascular disease events in obese individuals without T2D or concurrent cardiovascular disease.</p><p id="dom12954-para-0043">Pharmacological therapies for body weight loss have been associated historically with significant safety issues, leading to withdrawal of a number of agents.<xref rid="dom12954-bib-0007" ref-type="ref">7</xref> However, for these therapies to be accepted, they must possess a good safety profile when administered over an extended time period with the aim of reducing body weight and associated long&#x02010;term cardiometabolic risk. Even among currently approved treatments, careful patient selection is required to ensure safe use.<xref rid="dom12954-bib-0020" ref-type="ref">20</xref>
</p><p id="dom12954-para-0044">The separate safety profiles of dapagliflozin and exenatide have been evaluated in long&#x02010;term clinical trials in patients with T2D for up to 4&#x02009;years<xref rid="dom12954-bib-0056" ref-type="ref">56</xref> and 6&#x02009;years,<xref rid="dom12954-bib-0018" ref-type="ref">18</xref> respectively. The principal AEs with dapagliflozin (UTIs and genital infections) and exenatide (gastrointestinal symptoms and injection&#x02010;site reactions) tend to diminish with longer&#x02010;term exposure.<xref rid="dom12954-bib-0057" ref-type="ref">57</xref>, <xref rid="dom12954-bib-0058" ref-type="ref">58</xref> No unexpected AEs occurred with DAPA&#x02009;+&#x02009;ExQW dual therapy over 52&#x02009;weeks of follow&#x02010;up in this study. Discontinuations because of AEs with DAPA&#x02009;+&#x02009;ExQW (24.0% at 52&#x02009;weeks) in the current study were comparable to previous trials with various weight loss drugs.<xref rid="dom12954-bib-0025" ref-type="ref">25</xref> Moreover, in patients with T2D, the frequency of AEs was not overrepresented with DAPA&#x02009;+&#x02009;ExQW over 28&#x02009;weeks compared with each agent administered alone.<xref rid="dom12954-bib-0055" ref-type="ref">55</xref>
</p><p id="dom12954-para-0045">The current study has limitations. It was a small, single&#x02010;centre study without monotherapy comparator groups, making the effect size of each individual component difficult to assess. Placebo&#x02010;treated participants with more body weight loss during 0 to 24&#x02009;weeks showed a higher retention rate when entering the open&#x02010;label extension, indicating selection bias. However, our primary ITT analysis used MMRM, minimizing bias in delayed&#x02010;start clinical trials.<xref rid="dom12954-bib-0021" ref-type="ref">21</xref>
</p><p id="dom12954-para-0046">In this study, in which diet and exercise modification was not mandated or documented, dual therapy with DAPA&#x02009;+&#x02009;ExQW reduced and maintained body weight loss at approximately 5&#x02009;kg after 1&#x02009;year. This is similar to the placebo&#x02010;corrected effect of currently approved pharmacotherapies for obesity, whereas we found a greater effect of DAPA&#x02009;+&#x02009;ExQW on reduction in glycaemic parameters, prediabetes prevalence and SBP. This suggests a potential role for prevention of T2D and cardiovascular disease in this population. No unexpected safety and tolerability issues were observed with the combination of DAPA&#x02009;+&#x02009;ExQW, and rates of discontinuation because of AEs and study attrition were comparable to those with approved pharmacotherapies for obesity. Further studies evaluating long&#x02010;term effects on body weight, glucose metabolism and cardiovascular risk with DAPA&#x02009;+&#x02009;ExQW in conjunction with formal diet and exercise interventions are warranted.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="dom12954-supitem-0001"><caption><p id="dom12954-para-0001">
<bold>File S1.</bold>
</p><p id="dom12954-para-0002">
<bold>Table S1.</bold> Demographic and baseline characteristics.</p><p id="dom12954-para-0003">
<bold>Figure S1.</bold> Sensitivity analyses: <styled-content style="fixed-case">A</styled-content>, mean change in bodyweight among patients either entering or not entering the open&#x02010;label extension period; <styled-content style="fixed-case">B</styled-content>, adjusted mean change in bodyweight among patients entering the extension period; and <styled-content style="fixed-case">C</styled-content>, adjusted mean change in bodyweight among patients adhering to the protocol throughout the study. <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">DAPA&#x02009;+&#x02009;ExQW</styled-content>, dapagliflozin 10&#x02009;mg once daily plus exenatide 2&#x02009;mg once weekly; <styled-content style="fixed-case">PBO</styled-content>, placebo.</p><p id="dom12954-para-0004">
<bold>Figure S2.</bold> Change over time in liver fat percent units, defined as liver fat&#x02009;&#x000d7;&#x02009;100&#x02009;&#x000f7;&#x02009;(liver fat&#x02009;+&#x02009;liver water), for: <styled-content style="fixed-case">A</styled-content>, adjusted mean changes from baseline; <styled-content style="fixed-case">B</styled-content>, individual trajectories of change among <styled-content style="fixed-case">DAPA&#x02009;+&#x02009;ExQW</styled-content>&#x02010;treated participants; and <styled-content style="fixed-case">C</styled-content>, individual trajectories of change among <styled-content style="fixed-case">PBO</styled-content>&#x02010;treated participants. Data for <styled-content style="fixed-case">DAPA&#x02009;+&#x02009;ExQW</styled-content>&#x02010;treated participants were available at baseline, 24, and 52&#x02009;weeks; for <styled-content style="fixed-case">PBO</styled-content>&#x02010;treated patients, data were available only at baseline and at 24&#x02009;weeks. <styled-content style="fixed-case">CI</styled-content>, confidence interval; <styled-content style="fixed-case">DAPA&#x02009;+&#x02009;ExQW</styled-content>, dapagliflozin 10&#x02009;mg once daily plus exenatide 2&#x02009;mg once weekly; <styled-content style="fixed-case">PBO</styled-content>, placebo.</p></caption><media xlink:href="DOM-19-1276-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="dom12954-sec-0024"><title>ACKNOWLEDGEMENTS</title><p id="dom12954-para-0047">Lisa Baker and Julian Martins of inScience Communications, Springer Healthcare, and Amy Zannikos, on behalf of inScience Communications, Springer Healthcare, provided medical writing support that was funded by AstraZeneca. Mary Beth DeYoung and Elise Hardy of AstraZeneca critically reviewed the manuscript.</p><p id="dom12954-para-0048">This study was published previously, in part, in abstract form: Eriksson JW, Lundkvist P, Sj&#x000f6;str&#x000f6;m CD, et al. One year of treatment with dapagliflozin QD&#x02009;+&#x02009;exenatide QW in obese adults without diabetes: results of an open label extension study. Presented at the European Association for the Study of Diabetes Annual Meeting; September 12 to 16, 2016, Munich, Germany.</p><sec id="dom12954-sec-0025"><title>Conflict of interest</title><p id="dom12954-para-0049">P. L. has received an honorarium from Merck Sharp &#x00026; Dohme and a travel grant from AstraZeneca. M. J. P. and P. K. have no conflicts of interest to declare. C. D. S. and E. J. are employees of and own stock in AstraZeneca. J. W. E. has received research grants or honoraria from AstraZeneca, Bristol&#x02010;Myers Squibb, Merck Sharp &#x00026; Dohme, Novo Nordisk and Sanofi.</p></sec><sec id="dom12954-sec-0026"><title>Author contributions</title><p id="dom12954-para-0050">P. L. contributed to the conduct of the study, interpreting and discussing results, writing the manuscript and critically revising all subsequent versions. M. J. P. contributed to the design and conduct of the study, interpreting and discussing results, writing the manuscript and critically revising all subsequent versions. P. K. contributed to the conduct of the study and to critically revising all versions of the manuscript. C. D. S. and E. J. contributed to interpreting and discussing results, writing the manuscript and critically revising all subsequent versions. J. W. E. designed the study, contributed to the conduct of the study, interpreting and discussing results, writing the manuscript and critically revising all versions of the manuscript.</p></sec></ack><ref-list content-type="cited-references" id="dom12954-bibl-0001"><title>REFERENCES</title><ref id="dom12954-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="dom12954-cit-0001">
<collab collab-type="authors" id="dom12954-gp-0001">World Health Organization</collab>
. <article-title>Obesity and overweight: fact sheet no. 311</article-title>. <year>2016</year>
<ext-link ext-link-type="uri" xlink:href="http://www.who.int/mediacentre/factsheets/fs311/en/">http://www.who.int/mediacentre/factsheets/fs311/en/</ext-link>. Accessed February 2, 2016.</mixed-citation></ref><ref id="dom12954-bib-0002"><label>2</label><mixed-citation publication-type="book" id="dom12954-cit-0002">
<collab collab-type="authors" id="dom12954-gp-0002">International Diabetes Federation</collab>
. <source>IDF Diabetes Altas</source>. <edition>7th ed</edition>; <year>2015</year>
<ext-link ext-link-type="uri" xlink:href="http://www.diabetesatlas.org/">http://www.diabetesatlas.org/</ext-link>. Accessed February 15, 2016.</mixed-citation></ref><ref id="dom12954-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="dom12954-cit-0003">
<collab collab-type="authors" id="dom12954-gp-0003">Diabetes Prevention Program Research Group</collab>
. <article-title>Long&#x02010;term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15&#x02010;year follow&#x02010;up: the Diabetes Prevention Program Outcomes Study</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2015</year>;<volume>3</volume>:<fpage>866</fpage>&#x02010;<lpage>875</lpage>.<pub-id pub-id-type="pmid">26377054</pub-id></mixed-citation></ref><ref id="dom12954-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="dom12954-cit-0004">
<string-name>
<surname>Johns</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Hartmann&#x02010;Boyce</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jebb</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Aveyard</surname>
<given-names>P</given-names>
</string-name>. <article-title>Diet or exercise interventions vs combined behavioral weight management programs: a systematic review and meta&#x02010;analysis of direct comparisons</article-title>. <source>J Acad Nutr Diet</source>. <year>2014</year>;<volume>114</volume>:<fpage>1557</fpage>&#x02010;<lpage>1568</lpage>.<pub-id pub-id-type="pmid">25257365</pub-id></mixed-citation></ref><ref id="dom12954-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="dom12954-cit-0005">
<string-name>
<surname>Hartmann&#x02010;Boyce</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Johns</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Jebb</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Summerbell</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Aveyard</surname>
<given-names>P</given-names>
</string-name>. <article-title>Behavioural weight management programmes for adults assessed by trials conducted in everyday contexts: systematic review and meta&#x02010;analysis</article-title>. <source>Obes Rev</source>. <year>2014</year>;<volume>15</volume>:<fpage>920</fpage>&#x02010;<lpage>932</lpage>.<pub-id pub-id-type="pmid">25112559</pub-id></mixed-citation></ref><ref id="dom12954-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="dom12954-cit-0006">
<string-name>
<surname>Dhurandhar</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Kaiser</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Dawson</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Alcorn</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Keating</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Allison</surname>
<given-names>DB</given-names>
</string-name>. <article-title>Predicting adult weight change in the real world: a systematic review and meta&#x02010;analysis accounting for compensatory changes in energy intake or expenditure</article-title>. <source>Int J Obes</source>. <year>2015</year>;<volume>39</volume>:<fpage>1181</fpage>&#x02010;<lpage>1187</lpage>.</mixed-citation></ref><ref id="dom12954-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="dom12954-cit-0007">
<string-name>
<surname>Krentz</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Fujioka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hompesch</surname>
<given-names>M</given-names>
</string-name>. <article-title>Evolution of pharmacological obesity treatments: focus on adverse side&#x02010;effect profiles</article-title>. <source>Diabetes Obes Metab</source>. <year>2016</year>;<volume>18</volume>:<fpage>558</fpage>&#x02010;<lpage>570</lpage>.<pub-id pub-id-type="pmid">26936802</pub-id></mixed-citation></ref><ref id="dom12954-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="dom12954-cit-0008">
<string-name>
<surname>Halpern</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Oliveira</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Faria</surname>
<given-names>AM</given-names>
</string-name>, et al. <article-title>Combinations of drugs in the treatment of obesity</article-title>. <source>Pharmaceuticals</source>. <year>2010</year>;<volume>3</volume>:<fpage>2398</fpage>&#x02010;<lpage>2415</lpage>.<pub-id pub-id-type="pmid">27713360</pub-id></mixed-citation></ref><ref id="dom12954-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="dom12954-cit-0009">
<string-name>
<surname>Bays</surname>
<given-names>HE</given-names>
</string-name>, <string-name>
<surname>Weinstein</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Law</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Canovatchel</surname>
<given-names>W</given-names>
</string-name>. <article-title>Canagliflozin: effects in overweight and obese subjects without diabetes mellitus</article-title>. <source>Obesity</source>. <year>2014</year>;<volume>22</volume>:<fpage>1042</fpage>&#x02010;<lpage>1049</lpage>.<pub-id pub-id-type="pmid">24227660</pub-id></mixed-citation></ref><ref id="dom12954-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="dom12954-cit-0010">
<string-name>
<surname>Zhang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Tong</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Weight loss effect of glucagon&#x02010;like peptide&#x02010;1 mimetics on obese/overweight adults without diabetes: a systematic review and meta&#x02010;analysis of randomized controlled trials</article-title>. <source>J Diabetes</source>. <year>2015</year>;<volume>7</volume>:<fpage>329</fpage>&#x02010;<lpage>339</lpage>.<pub-id pub-id-type="pmid">25043423</pub-id></mixed-citation></ref><ref id="dom12954-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="dom12954-cit-0011">
<string-name>
<surname>Lambers Heerspink</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>de Zeeuw</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wie</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Leslie</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>List</surname>
<given-names>J</given-names>
</string-name>. <article-title>Dapagliflozin a glucose&#x02010;regulating drug with diuretic properties in subjects with type 2 diabetes</article-title>. <source>Diabetes Obes Metab</source>. <year>2013</year>;<volume>15</volume>:<fpage>853</fpage>&#x02010;<lpage>862</lpage>.<pub-id pub-id-type="pmid">23668478</pub-id></mixed-citation></ref><ref id="dom12954-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="dom12954-cit-0012">
<string-name>
<surname>Ferrannini</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hach</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Crowe</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sanghvi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hall</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Ferrannini</surname>
<given-names>E</given-names>
</string-name>. <article-title>Energy balance after sodium&#x02010;glucose cotransporter 2 inhibition</article-title>. <source>Diabetes Care</source>. <year>2015</year>;<volume>38</volume>:<fpage>1730</fpage>&#x02010;<lpage>1735</lpage>.<pub-id pub-id-type="pmid">26180105</pub-id></mixed-citation></ref><ref id="dom12954-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="dom12954-cit-0013">
<string-name>
<surname>van Bloemendaal</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ten Kulve</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>la Fleur</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Ijzerman</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Diamant</surname>
<given-names>M</given-names>
</string-name>. <article-title>Effects of glucagon&#x02010;like peptide 1 on appetite and body weight: focus on the CNS</article-title>. <source>J Endocrinol</source>. <year>2014</year>;<volume>221</volume>:<fpage>T1</fpage>&#x02010;<lpage>T16</lpage>.<pub-id pub-id-type="pmid">24323912</pub-id></mixed-citation></ref><ref id="dom12954-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="dom12954-cit-0014">
<string-name>
<surname>Bailey</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Morales Villegas</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Woo</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Ptaszynska</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>List</surname>
<given-names>JF</given-names>
</string-name>. <article-title>Efficacy and safety of dapagliflozin monotherapy in people with type 2 diabetes: a randomized double&#x02010;blind placebo&#x02010;controlled 102&#x02010;week trial</article-title>. <source>Diabet Med</source>. <year>2015</year>;<volume>32</volume>:<fpage>531</fpage>&#x02010;<lpage>541</lpage>.<pub-id pub-id-type="pmid">25381876</pub-id></mixed-citation></ref><ref id="dom12954-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="dom12954-cit-0015">
<string-name>
<surname>Bolinder</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ljunggren</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Johansson</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin</article-title>. <source>Diabetes Obes Metab</source>. <year>2014</year>;<volume>16</volume>:<fpage>159</fpage>&#x02010;<lpage>169</lpage>.<pub-id pub-id-type="pmid">23906445</pub-id></mixed-citation></ref><ref id="dom12954-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="dom12954-cit-0016">
<string-name>
<surname>Wilding</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Woo</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Rohwedder</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sugg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Parikh</surname>
<given-names>S</given-names>
</string-name>. <article-title>Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years</article-title>. <source>Diabetes Obes Metab</source>. <year>2014</year>;<volume>16</volume>:<fpage>124</fpage>&#x02010;<lpage>136</lpage>.<pub-id pub-id-type="pmid">23911013</pub-id></mixed-citation></ref><ref id="dom12954-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="dom12954-cit-0017">
<string-name>
<surname>Diamant</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Van Gaal</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Guerci</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION&#x02010;3): 3&#x02010;year results of an open&#x02010;label randomised trial</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2014</year>;<volume>2</volume>:<fpage>464</fpage>&#x02010;<lpage>473</lpage>.<pub-id pub-id-type="pmid">24731672</pub-id></mixed-citation></ref><ref id="dom12954-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="dom12954-cit-0018">
<string-name>
<surname>Henry</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Klein</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Iqbal</surname>
<given-names>N</given-names>
</string-name>. <article-title>Efficacy and tolerability of exenatide once weekly over 6 years in patients with type 2 diabetes: an uncontrolled open&#x02010;label extension of the DURATION&#x02010;1 study</article-title>. <source>Diabetes Technol Ther</source>. <year>2016</year>;<volume>18</volume>:<fpage>677</fpage>&#x02010;<lpage>686</lpage>.<pub-id pub-id-type="pmid">27525540</pub-id></mixed-citation></ref><ref id="dom12954-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="dom12954-cit-0019">
<string-name>
<surname>Wysham</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>MacConell</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Maggs</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Griffin</surname>
<given-names>PS</given-names>
</string-name>, <string-name>
<surname>Trautmann</surname>
<given-names>ME</given-names>
</string-name>. <article-title>Five&#x02010;year efficacy and safety data of exenatide once weekly: long&#x02010;term results from the DURATION&#x02010;1 randomized clinical trial</article-title>. <source>Mayo Clin Proc</source>. <year>2015</year>;<volume>90</volume>:<fpage>356</fpage>&#x02010;<lpage>365</lpage>.<pub-id pub-id-type="pmid">25744115</pub-id></mixed-citation></ref><ref id="dom12954-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="dom12954-cit-0020">
<string-name>
<surname>Lundkvist</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sj&#x000f6;str&#x000f6;m</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Amini</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pereira</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Johnsson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Eriksson</surname>
<given-names>JW</given-names>
</string-name>. <article-title>Dapagliflozin once&#x02010;daily and exenatide once&#x02010;weekly dual therapy: a 24&#x02010;week randomized, placebo&#x02010;controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes</article-title>. <source>Diabetes Obes Metab</source>. <year>2017</year>;<volume>19</volume>:<fpage>49</fpage>&#x02010;<lpage>60</lpage>.<pub-id pub-id-type="pmid">27550386</pub-id></mixed-citation></ref><ref id="dom12954-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="dom12954-cit-0021">
<string-name>
<surname>Liu&#x02010;Seifert</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Andersen</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Lipkovich</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Holdridge</surname>
<given-names>KC</given-names>
</string-name>, <string-name>
<surname>Siemers</surname>
<given-names>E</given-names>
</string-name>. <article-title>A novel approach to delayed&#x02010;start analyses for demonstrating disease&#x02010;modifying effects in Alzheimer's disease</article-title>. <source>PLoS ONE</source>. <year>2015</year>;<volume>10</volume>:<fpage>e0119632</fpage>.<pub-id pub-id-type="pmid">25781335</pub-id></mixed-citation></ref><ref id="dom12954-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="dom12954-cit-0022">
<string-name>
<surname>Leibel</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Rosenbaum</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hirsch</surname>
<given-names>J</given-names>
</string-name>. <article-title>Changes in energy expenditure resulting from altered body weight</article-title>. <source>N Engl J Med</source>. <year>1995</year>;<volume>332</volume>:<fpage>621</fpage>&#x02010;<lpage>628</lpage>.<pub-id pub-id-type="pmid">7632212</pub-id></mixed-citation></ref><ref id="dom12954-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="dom12954-cit-0023">
<string-name>
<surname>Boswell</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Kober</surname>
<given-names>H</given-names>
</string-name>. <article-title>Food cue reactivity and craving predict eating and weight gain: a meta&#x02010;analytic review</article-title>. <source>Obes Rev</source>. <year>2016</year>;<volume>17</volume>:<fpage>159</fpage>&#x02010;<lpage>177</lpage>.<pub-id pub-id-type="pmid">26644270</pub-id></mixed-citation></ref><ref id="dom12954-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="dom12954-cit-0024">
<string-name>
<surname>Apovian</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Aronne</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Bessesen</surname>
<given-names>DH</given-names>
</string-name>, et al. <article-title>Pharmacological management of obesity: an Endocrine Society clinical practice guideline</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2015</year>;<volume>100</volume>:<fpage>342</fpage>&#x02010;<lpage>362</lpage>.<pub-id pub-id-type="pmid">25590212</pub-id></mixed-citation></ref><ref id="dom12954-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="dom12954-cit-0025">
<string-name>
<surname>Khera</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Murad</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Chandar</surname>
<given-names>AK</given-names>
</string-name>, et al. <article-title>Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta&#x02010;analysis</article-title>. <source>JAMA</source>. <year>2016</year>;<volume>315</volume>:<fpage>2424</fpage>&#x02010;<lpage>2434</lpage>.<pub-id pub-id-type="pmid">27299618</pub-id></mixed-citation></ref><ref id="dom12954-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="dom12954-cit-0026">
<string-name>
<surname>Kasichayanula</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Lacreta</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Griffen</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Boulton</surname>
<given-names>DW</given-names>
</string-name>. <article-title>Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium&#x02010;glucose co&#x02010;transporter type 2</article-title>. <source>Clin Pharmacokinet</source>. <year>2014</year>;<volume>53</volume>:<fpage>17</fpage>&#x02010;<lpage>27</lpage>.<pub-id pub-id-type="pmid">24105299</pub-id></mixed-citation></ref><ref id="dom12954-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="dom12954-cit-0027">
<string-name>
<surname>Astrup</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rossner</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Van Gaal</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Effects of liraglutide in the treatment of obesity: a randomised, double&#x02010;blind, placebo&#x02010;controlled study</article-title>. <source>Lancet</source>. <year>2009</year>;<volume>374</volume>:<fpage>1606</fpage>&#x02010;<lpage>1616</lpage>.<pub-id pub-id-type="pmid">19853906</pub-id></mixed-citation></ref><ref id="dom12954-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="dom12954-cit-0028">
<string-name>
<surname>Astrup</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Carraro</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Finer</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Safety, tolerability and sustained weight loss over 2 years with the once&#x02010;daily human GLP&#x02010;1 analog, liraglutide</article-title>. <source>Int J Obes</source>. <year>2012</year>;<volume>36</volume>:<fpage>843</fpage>&#x02010;<lpage>854</lpage>.</mixed-citation></ref><ref id="dom12954-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="dom12954-cit-0029">
<string-name>
<surname>Pi&#x02010;Sunyer</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Astrup</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fujioka</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>A randomized, controlled trial of 3.0&#x02009;mg of liraglutide in weight management</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>373</volume>:<fpage>11</fpage>&#x02010;<lpage>22</lpage>.<pub-id pub-id-type="pmid">26132939</pub-id></mixed-citation></ref><ref id="dom12954-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="dom12954-cit-0030">
<string-name>
<surname>Torgerson</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Hauptman</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Boldrin</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Sj&#x000f6;str&#x000f6;m</surname>
<given-names>L</given-names>
</string-name>. <article-title>XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients</article-title>. <source>Diabetes Care</source>. <year>2004</year>;<volume>27</volume>:<fpage>155</fpage>&#x02010;<lpage>161</lpage>.<pub-id pub-id-type="pmid">14693982</pub-id></mixed-citation></ref><ref id="dom12954-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="dom12954-cit-0031">
<string-name>
<surname>Krempf</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Louvet</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Allanic</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Miloradovich</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Joubert</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Attali</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Weight reduction and long&#x02010;term maintenance after 18 months treatment with orlistat for obesity</article-title>. <source>Int J Obes Relat Metab Disord</source>. <year>2003</year>;<volume>27</volume>:<fpage>591</fpage>&#x02010;<lpage>597</lpage>.<pub-id pub-id-type="pmid">12704403</pub-id></mixed-citation></ref><ref id="dom12954-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="dom12954-cit-0032">
<string-name>
<surname>Broom</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Wilding</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Stott</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Myers</surname>
<given-names>N</given-names>
</string-name>. <article-title>Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study</article-title>. <source>Int J Clin Pract</source>. <year>2002</year>;<volume>56</volume>:<fpage>494</fpage>&#x02010;<lpage>499</lpage>.<pub-id pub-id-type="pmid">12296610</pub-id></mixed-citation></ref><ref id="dom12954-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="dom12954-cit-0033">
<string-name>
<surname>Rossner</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sj&#x000f6;str&#x000f6;m</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Noack</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Meinders</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Noseda</surname>
<given-names>G</given-names>
</string-name>. <article-title>Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group</article-title>. <source>Obes Res</source>. <year>2000</year>;<volume>8</volume>:<fpage>49</fpage>&#x02010;<lpage>61</lpage>.<pub-id pub-id-type="pmid">10678259</pub-id></mixed-citation></ref><ref id="dom12954-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="dom12954-cit-0034">
<string-name>
<surname>Hauptman</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lucas</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Boldrin</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Collins</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Segal</surname>
<given-names>KR</given-names>
</string-name>. <article-title>Orlistat in the long&#x02010;term treatment of obesity in primary care settings</article-title>. <source>Arch Fam Med</source>. <year>2000</year>;<volume>9</volume>:<fpage>160</fpage>&#x02010;<lpage>167</lpage>.<pub-id pub-id-type="pmid">10693734</pub-id></mixed-citation></ref><ref id="dom12954-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="dom12954-cit-0035">
<string-name>
<surname>Davidson</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Hauptman</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>DiGirolamo</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial</article-title>. <source>JAMA</source>. <year>1999</year>;<volume>281</volume>:<fpage>235</fpage>&#x02010;<lpage>242</lpage>.<pub-id pub-id-type="pmid">9918478</pub-id></mixed-citation></ref><ref id="dom12954-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="dom12954-cit-0036">
<string-name>
<surname>Sj&#x000f6;str&#x000f6;m</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Rissanen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Andersen</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Randomised placebo&#x02010;controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group</article-title>. <source>Lancet</source>. <year>1998</year>;<volume>352</volume>:<fpage>167</fpage>&#x02010;<lpage>172</lpage>.<pub-id pub-id-type="pmid">9683204</pub-id></mixed-citation></ref><ref id="dom12954-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="dom12954-cit-0037">
<string-name>
<surname>Fidler</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Sanchez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Raether</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>A one&#x02010;year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2011</year>;<volume>96</volume>:<fpage>3067</fpage>&#x02010;<lpage>3077</lpage>.<pub-id pub-id-type="pmid">21795446</pub-id></mixed-citation></ref><ref id="dom12954-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="dom12954-cit-0038">
<string-name>
<surname>Smith</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Weissman</surname>
<given-names>NJ</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>CM</given-names>
</string-name>, et al. <article-title>Multicenter, placebo&#x02010;controlled trial of lorcaserin for weight management</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>:<fpage>245</fpage>&#x02010;<lpage>256</lpage>.<pub-id pub-id-type="pmid">20647200</pub-id></mixed-citation></ref><ref id="dom12954-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="dom12954-cit-0039">
<string-name>
<surname>Apovian</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Aronne</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Rubino</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity&#x02010;related risk factors (COR&#x02010;II)</article-title>. <source>Obesity</source>. <year>2013</year>;<volume>21</volume>:<fpage>935</fpage>&#x02010;<lpage>943</lpage>.<pub-id pub-id-type="pmid">23408728</pub-id></mixed-citation></ref><ref id="dom12954-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="dom12954-cit-0040">
<string-name>
<surname>Wadden</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Foreyt</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Foster</surname>
<given-names>GD</given-names>
</string-name>, et al. <article-title>Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR&#x02010;BMOD trial</article-title>. <source>Obesity</source>. <year>2011</year>;<volume>19</volume>:<fpage>110</fpage>&#x02010;<lpage>120</lpage>.<pub-id pub-id-type="pmid">20559296</pub-id></mixed-citation></ref><ref id="dom12954-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="dom12954-cit-0041">
<string-name>
<surname>Greenway</surname>
<given-names>FL</given-names>
</string-name>, <string-name>
<surname>Fujioka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Plodkowski</surname>
<given-names>RA</given-names>
</string-name>, et al. <article-title>Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR&#x02010;I): a multicentre, randomised, double&#x02010;blind, placebo&#x02010;controlled, phase 3 trial</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>376</volume>:<fpage>595</fpage>&#x02010;<lpage>605</lpage>.<pub-id pub-id-type="pmid">20673995</pub-id></mixed-citation></ref><ref id="dom12954-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="dom12954-cit-0042">
<string-name>
<surname>Allison</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Gadde</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Garvey</surname>
<given-names>WT</given-names>
</string-name>, et al. <article-title>Controlled&#x02010;release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)</article-title>. <source>Obesity</source>. <year>2012</year>;<volume>20</volume>:<fpage>330</fpage>&#x02010;<lpage>342</lpage>.<pub-id pub-id-type="pmid">22051941</pub-id></mixed-citation></ref><ref id="dom12954-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="dom12954-cit-0043">
<string-name>
<surname>Zinman</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wanner</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lachin</surname>
<given-names>JM</given-names>
</string-name>, et al. <article-title>Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>373</volume>:<fpage>2117</fpage>&#x02010;<lpage>2128</lpage>.<pub-id pub-id-type="pmid">26378978</pub-id></mixed-citation></ref><ref id="dom12954-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="dom12954-cit-0044">
<string-name>
<surname>Wu</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Foote</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Blomster</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Effects of sodium&#x02010;glucose cotransporter&#x02010;2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta&#x02010;analysis</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2016</year>;<volume>4</volume>:<fpage>411</fpage>&#x02010;<lpage>419</lpage>.<pub-id pub-id-type="pmid">27009625</pub-id></mixed-citation></ref><ref id="dom12954-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="dom12954-cit-0045">
<string-name>
<surname>Marso</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Daniels</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Brown&#x02010;Frandsen</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Liraglutide and cardiovascular outcomes in type 2 diabetes</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>375</volume>:<fpage>311</fpage>&#x02010;<lpage>322</lpage>.<pub-id pub-id-type="pmid">27295427</pub-id></mixed-citation></ref><ref id="dom12954-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="dom12954-cit-0046">
<string-name>
<surname>Marso</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Bain</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Consoli</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Semaglutide and cardiovascular outcomes in patients with type 2 diabetes</article-title>. <source>N Engl J Med</source>. <year>2016</year>;<volume>375</volume>:<fpage>1834</fpage>&#x02010;<lpage>1844</lpage>.<pub-id pub-id-type="pmid">27633186</pub-id></mixed-citation></ref><ref id="dom12954-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="dom12954-cit-0047">
<string-name>
<surname>Sonesson</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Johansson</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Johnsson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Gause&#x02010;Nilsson</surname>
<given-names>I</given-names>
</string-name>. <article-title>Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta&#x02010;analysis</article-title>. <source>Cardiovasc Diabetol</source>. <year>2016</year>;<volume>15</volume>:<fpage>37</fpage>.<pub-id pub-id-type="pmid">26895767</pub-id></mixed-citation></ref><ref id="dom12954-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="dom12954-cit-0048">
<string-name>
<surname>Monami</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dicembrini</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Nardini</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fiordelli</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Mannucci</surname>
<given-names>E</given-names>
</string-name>. <article-title>Effects of glucagon&#x02010;like peptide&#x02010;1 receptor agonists on cardiovascular risk: a meta&#x02010;analysis of randomized clinical trials</article-title>. <source>Diabetes Obes Metab</source>. <year>2014</year>;<volume>16</volume>:<fpage>38</fpage>&#x02010;<lpage>47</lpage>.<pub-id pub-id-type="pmid">23829656</pub-id></mixed-citation></ref><ref id="dom12954-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="dom12954-cit-0049">
<string-name>
<surname>Holman</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Bethel</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>George</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial</article-title>. <source>Am Heart J</source>. <year>2016</year>;<volume>174</volume>:<fpage>103</fpage>&#x02010;<lpage>110</lpage>.<pub-id pub-id-type="pmid">26995376</pub-id></mixed-citation></ref><ref id="dom12954-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="dom12954-cit-0050">
<string-name>
<surname>Rajasekeran</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lytvyn</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Cherney</surname>
<given-names>DZ</given-names>
</string-name>. <article-title>Sodium&#x02010;glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis</article-title>. <source>Kidney Int</source>. <year>2016</year>;<volume>89</volume>:<fpage>524</fpage>&#x02010;<lpage>526</lpage>.<pub-id pub-id-type="pmid">26880444</pub-id></mixed-citation></ref><ref id="dom12954-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="dom12954-cit-0051">
<string-name>
<surname>Mudaliar</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Alloju</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Henry</surname>
<given-names>RR</given-names>
</string-name>. <article-title>Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA&#x02010;REG OUTCOME Study? A unifying hypothesis</article-title>. <source>Diabetes Care</source>. <year>2016</year>;<volume>39</volume>:<fpage>1115</fpage>&#x02010;<lpage>1122</lpage>.<pub-id pub-id-type="pmid">27289124</pub-id></mixed-citation></ref><ref id="dom12954-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="dom12954-cit-0052">
<string-name>
<surname>Gilbert</surname>
<given-names>RE</given-names>
</string-name>. <article-title>SGLT2 inhibitors: beta blockers for the kidney?</article-title>
<source>Lancet Diabetes Endocrinol</source>. <year>2016</year>;<volume>4</volume>:<fpage>814</fpage>.<pub-id pub-id-type="pmid">27663956</pub-id></mixed-citation></ref><ref id="dom12954-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="dom12954-cit-0053">
<string-name>
<surname>Irace</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>De Luca</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Shehaj</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research</article-title>. <source>Diab Vasc Dis Res</source>. <year>2013</year>;<volume>10</volume>:<fpage>72</fpage>&#x02010;<lpage>77</lpage>.<pub-id pub-id-type="pmid">22732108</pub-id></mixed-citation></ref><ref id="dom12954-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="dom12954-cit-0054">
<string-name>
<surname>Mendis</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>MacDonald</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Mansell</surname>
<given-names>P</given-names>
</string-name>. <article-title>Investigation of the haemodynamic effects of exenatide in healthy male subjects</article-title>. <source>Br J Clin Pharmacol</source>. <year>2012</year>;<volume>74</volume>:<fpage>437</fpage>&#x02010;<lpage>444</lpage>.<pub-id pub-id-type="pmid">22320349</pub-id></mixed-citation></ref><ref id="dom12954-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="dom12954-cit-0055">
<string-name>
<surname>Fr&#x000ed;as</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Guja</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hardy</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION&#x02010;8): a 28 week, multicentre, double&#x02010;blind, phase 3, randomised controlled trial</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2016</year>;<volume>4</volume>:<fpage>1004</fpage>&#x02010;<lpage>1016</lpage>.<pub-id pub-id-type="pmid">27651331</pub-id></mixed-citation></ref><ref id="dom12954-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="dom12954-cit-0056">
<string-name>
<surname>Del Prato</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nauck</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dur&#x000e1;n&#x02010;Garcia</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Long&#x02010;term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add&#x02010;on therapy to metformin in patients with type 2 diabetes: 4&#x02010;year data</article-title>. <source>Diabetes Obes Metab</source>. <year>2015</year>;<volume>17</volume>:<fpage>581</fpage>&#x02010;<lpage>590</lpage>.<pub-id pub-id-type="pmid">25735400</pub-id></mixed-citation></ref><ref id="dom12954-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="dom12954-cit-0057">
<string-name>
<surname>Ptaszynska</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Johnsson</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Parikh</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>de Bruin</surname>
<given-names>TW</given-names>
</string-name>, <string-name>
<surname>Apanovitch</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>List</surname>
<given-names>JF</given-names>
</string-name>. <article-title>Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events</article-title>. <source>Drug Saf</source>. <year>2014</year>;<volume>37</volume>:<fpage>815</fpage>&#x02010;<lpage>829</lpage>.<pub-id pub-id-type="pmid">25096959</pub-id></mixed-citation></ref><ref id="dom12954-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="dom12954-cit-0058">
<string-name>
<surname>Horowitz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Aroda</surname>
<given-names>VR</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hardy</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Rayner</surname>
<given-names>C</given-names>
</string-name>. <article-title>Upper and/or lower GI adverse events with long&#x02010; vs short&#x02010;acting GLP&#x02010;1 receptor agonists: incidence, co&#x02010;incidence, effects on HbA1c and weight [abstract 15]</article-title>. <source>Diabetologia</source>. <year>2015</year>;<volume>58</volume>
<issue>(suppl)</issue>:<fpage>S7</fpage>.</mixed-citation></ref></ref-list></back></article>